How many Semaglutide clinical trials are there?

537 Semaglutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 114 are actively recruiting participants. 279 are marked completed.

Are Semaglutide clinical trials recruiting in 2026?

Yes — 114 Semaglutide trials are actively recruiting in 2026, with 195 U.S. sites across 37 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Semaglutide being studied for?

Semaglutide is being studied for Diabetes Mellitus, Type 2, Obesity, Diabetes, Type 2 Diabetes, Overweight and 329 more. The trials are grouped by indication on this page.

What phase is Semaglutide in?

Semaglutide clinical trials span 85 Phase 4, 138 Phase 3, 95 Phase 2, 104 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Semaglutide clinical trials?

The lead sponsor across the most Semaglutide trials is Novo Nordisk A/S, with 213 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Semaglutide Clinical Trials (2026): 537 Studies for Diabetes Mellitus, Type 2 & Obesity

Creator: Hipa.ai Research
Published: 2026-05-08T18:55:30.985Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

537 Semaglutide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 170 indications (including Diabetes Mellitus, Type 2 & Obesity) and 2,376,257 total planned enrollment. 138 Phase 3 Semaglutide trials and 95 Phase 2, 85 Phase 4 are listed. 164 Semaglutide clinical trials are actively recruiting at 195 U.S. sites across 37 states. Most recent activity: NCT05441267 (Aug 2048).

Where to Participate: All Semaglutide Trial Sites in the U.S. (195 sites across 37 states)

Every actively recruiting Semaglutidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Cahaba Research	Pelham35124	NCT07564414	Map
AZ	Kailera Clinical Site	Glendale85308	NCT07284979	Map
AZ	DM Clinical Research - Phoenix	Phoenix85012	NCT07446998	Map
AZ	Kailera Clinical Site	Phoenix85012	NCT07284979	Map
AZ	Velocity Clinical Research-Phoenix	Phoenix85006	NCT07564414	Map
AR	Arkansas Clinical Research	Little Rock72205	NCT07564414	Map
AR	Kailera Clinical Site	Little Rock72205	NCT07284979	Map
CA	Altasciences Clinical LA, Inc.	Cypress90630	NCT07225816	Map
CA	City of Hope Medical Center	Duarte91010	NCT07202247	Map
CA	Headlands Research California, LLC	Escondido92025	NCT07564414	Map
CA	Neighborhood Healthcare	Escondido92025	NCT07564414	Map
CA	Diabetes & Endocrine Specialists - La Mesa	La Mesa91942	NCT07564414	Map
CA	First Valley Medical Group	Lancaster93534	NCT07415954	Map
CA	Clinical Trials Research_Sacramento	Lincoln95648	NCT07564414	Map
CA	Torrance Clinical Research Institute, Inc.	Lomita90717	NCT07415954	Map
CA	Ark Clinical Research	Long Beach90815	NCT07415954	Map
CA	Pacific Clinical Studies	Los Alamitos90720	NCT07415954	Map
CA	Pacific Clinical Studies	Los Alamitos90720	NCT07564414	Map
CA	UCLA Health	Los Angeles90095	NCT05419726	Map
CA	Kailera Clinical Site	Northridge91325	NCT07284979	Map
CA	Valley Clinical Trials	Northridge91325	NCT07564414	Map
CA	Kailera Clinical Site	Oceanside92058	NCT07284979	Map
CA	Desert Oasis Healthcare	Palm Springs92262	NCT07564414	Map
CA	Greenstone Biosciences	Palo Alto94304	NCT06541509	Map
CA	Linda Vista Health Care Ctr	San Diego92111	NCT07564414	Map
CA	Wetlin Research Associates, Inc.	San Diego92120	NCT07415954	Map
CA	Center on Substance Use and Health	San Francisco94102	NCT07204249	Map
CA	Stanford Cardiovascular Institute	Stanford94305	NCT06541509	Map
CA	Stanford University	Stanford94305	NCT05173714	Map
CA	Velocity Clin Res - Van Nuys	Van Nuys91405	NCT07564414	Map
CA	Diablo Clinical Research, Inc.	Walnut Creek94598	NCT07415954	Map
CA	Flourish Research - CA	Walnut Creek94598	NCT07564414	Map
CO	Childrens Hospital Colorado	Aurora80045	NCT06575738	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT05819138	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT05822609	Map
CO	University of Colorado Anschutz/Children's Hospital Colorado Aurora	Aurora80045	NCT05819853	Map
CO	University of Colorado-School of Medicine	Aurora80045	NCT06975111	Map
CT	Kailera Clinical Site	Hamden06517	NCT07284979	Map
CT	Yale Pediatric Diabetes Center, Adult and Children's Progam	New Haven06520	NCT06411210	Map
CT	Yale School of Medicine	New Haven06520	NCT07223983	Map
CT	Kailera Clinical Site	Stamford06905	NCT07284979	Map
DC	Institute of Human Virology at the University of Maryland School of Medicine	Washington D.C.20002	NCT06691243	Map
FL	TBMR & Alcanza	Clearwater33761	NCT07564414	Map
FL	DM Clinical Research - MIA	Doral33166	NCT07446998	Map
FL	Universal Axon Clinical Research (Rovia - UACR)	Doral33166	NCT07446998	Map
FL	Northeast Research Institute	Fleming Island32003	NCT07564414	Map
FL	Encore Medical Research LLC	Hollywood33024	NCT07253285	Map
FL	Encore Medical Research LLC	Hollywood33024	NCT07415954	Map
FL	Northeast Research Institute	Jacksonville32204	NCT07564414	Map
FL	Bioclinical Research Alliance	Miami33155	NCT07415954	Map
FL	Bioclinical Research Alliance	Miami33155	NCT07564414	Map
FL	IMIC Research a Rovia Clinical Research Company	Miami33176	NCT07446998	Map
FL	New Horizon Research Center	Miami33165	NCT07564414	Map
FL	Paramo Health	Miami33175	NCT07446998	Map
FL	Paramo Health	Miami33176	NCT07446998	Map
FL	South Broward Research LLC	Miramar33027	NCT07415954	Map
FL	South Broward Research LLC	Miramar33027	NCT07564414	Map
FL	West Orange Endocrinology	Ocoee34761	NCT07564414	Map
FL	Kailera Clinical Site	Orange City32763	NCT07284979	Map
FL	Advent Health-Res Inst	Orlando32804	NCT07184086	Map
FL	Oviedo Medical Research, LLC	Oviedo32765	NCT07564414	Map
FL	Encore Medical Research of Weston	Weston33331	NCT07253285	Map
FL	Encore Medical Research of Weston	Weston33331	NCT07415954	Map
GA	Kailera Clinical Site	Albany31707	NCT07284979	Map
GA	Children's Healthcare Atlanta	Atlanta30329	NCT07253285	Map
GA	UD Research	Atlanta30342	NCT07446998	Map
GA	Columbus Research Foundation	Columbus31904	NCT07253285	Map
GA	Hope Clin Res & Wellness	Conyers30094	NCT07564414	Map
GA	Accel Research Sites-NeuroStudies	Decatur30030	NCT07253285	Map
GA	Atlanta VA Medical Center	Decatur30033	NCT07040592	Map
GA	Center for Adv Res & Education	Gainesville30501	NCT07564414	Map
GA	Endocrine Research Solutions, Inc	Roswell30076	NCT07564414	Map
GA	Eastside Bariatric and Gen Surg	Snellville30078	NCT07253285	Map
GA	North Georgia Clinical Research	Woodstock30189-4255	NCT07564414	Map
ID	Elite Clinical Trials	Blackfoot83221	NCT07415954	Map
ID	Solaris Clinical Research	Meridian83646	NCT07564414	Map
IL	Cedar-Crosse Research Center	Chicago60607	NCT07415954	Map
IL	Kailera Clinical Site	Chicago60640	NCT07284979	Map
IL	University of Chicago	Chicago60637	NCT06499857	Map
IL	Macoupin Fam Practice Ctr, LLP	Gillespie62033	NCT07564414	Map
IL	Clinical Investigation Spec Gurnee	Gurnee60031	NCT07564414	Map
IL	Evanston Premier Hlthcr Res	Skokie60077	NCT07564414	Map
IL	Kailera Clinical Site	Skokie60077	NCT07284979	Map
IN	IU Health - Riley Physicians Endo-Diab	Indianapolis46202	NCT07253285	Map
KS	Alliance for Multispecialty Research	Newton67114	NCT07564414	Map
KS	Kailera Clinical Site	Newton67114	NCT07284979	Map
KS	Cotton O'Neil Diab & Endo Ctr	Topeka66606	NCT07564414	Map
KY	The Research Group of Lexington LLC	Lexington40503	NCT07564414	Map
LA	Pennington Biomed Res Ctr	Baton Rouge70808-4124	NCT07184086	Map
LA	Pennington Biomed Res Ctr	Baton Rouge70808-4124	NCT07253285	Map
LA	Pennington Biomedical Research Center	Baton Rouge70808	NCT07446998	Map
LA	Woman's Hospital	Baton Rouge70817	NCT04873050	Map
LA	Kailera Clinical Site	Shreveport71105	NCT07284979	Map
MD	Institute of Human Virology at the University of Maryland School of Medicine	Baltimore21201	NCT06691243	Map
MD	National Institute on Drug Abuse	Baltimore21224	NCT06015893	Map
MD	University of Maryland Baltimore	Baltimore21223	NCT06548490	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT03884075	Map
MD	Centennial Medical Group (CMG)	Columbia21045	NCT07446998	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06639464	Map
MA	Massachusetts General Hospital	Boston02114	NCT06003153	Map
MI	Northern Pines Hlth Ctr, PC	Buckley49620	NCT07564414	Map
MI	Kailera Clinical Site	Farmington Hills48334	NCT07284979	Map
MN	University of Minnesota	Minneapolis55455	NCT07253285	Map
MN	AES Minneapolis DRS	Richfield55423	NCT07564414	Map
MN	Mayo Clinic	Rochester55905	NCT07213466	Map
MS	SKY Integrative Medical Center	Ridgeland39157	NCT07446998	Map
MO	Clinical Research Professionals	Chesterfield63005	NCT07564414	Map
MO	Headlands Research	Springfield65807	NCT07415954	Map
MO	Amicis Centers of Clinical Research	St Louis63128	NCT07564414	Map
MO	Washington University School of Medicine	St Louis63110	NCT07091500	Map
MT	Kailera Clinical Site	Missoula59804	NCT07284979	Map
NV	Kailera Clinical Site	Las Vegas89148	NCT07284979	Map
NJ	Frontage Clinical Services, Inc.	Secaucus07094	NCT07465965	Map
NY	Kailera Clinical Site	Albany12203	NCT07284979	Map
NY	NYU Langone Health	New York10016	NCT06548490	Map
NY	Southgate Medical Group, LLP	West Seneca14224	NCT07564414	Map
NC	PharmQuest	Greensboro27408	NCT07415954	Map
NC	PharmQuest Life Sciences LLC	Greensboro27408	NCT07564414	Map
NC	Physician's East Endocrinology	Greenville27834	NCT07564414	Map
NC	Carteret Medical Group	Morehead City28557	NCT07564414	Map
NC	Centricity Rsrch MHCity Multi	Morehead City28557	NCT07564414	Map
NC	Kailera Clinical Site	Morehead City28557	NCT07284979	Map
NC	Piedmont Healthcare Statesville	Statesville28625	NCT07415954	Map
NC	Piedmont Healthcare/Research	Statesville28625	NCT07564414	Map
NC	Accellacare Wilmington	Wilmington28401	NCT07564414	Map
ND	Lillestol Research LLC	Fargo58104	NCT07564414	Map
OH	Providence Center for Clinical Research	Dayton45439	NCT07415954	Map
OH	Advanced Medical Research	Maumee43537	NCT07564414	Map
OK	Alliance for Multispecialty Research	Norman73069	NCT07564414	Map
OK	Kailera Clinical Site	Norman73069	NCT07284979	Map
OK	Lynn Institute of Norman	Norman73072	NCT07564414	Map
OK	Health Promotion Research Center	Oklahoma City73104	NCT06986993	Map
PA	Pennsylvania Psychiatric Institute	Harrisburg17110	NCT06548490	Map
PA	Hatboro Med Associates	Hatboro19040	NCT07564414	Map
PA	Amish Research Clinic	Lancaster17602	NCT05071898	Map
PA	University of Pennsylvania Perelman School of Medicine	Philadelphia19104	NCT05746039	Map
RI	Clinical Res Collaborative	Cumberland02864	NCT07564414	Map
RI	Kailera Clinical Site	East Greenwich02818	NCT07284979	Map
SC	Kailera Clinical Site	North Charleston29405	NCT07284979	Map
SC	Kailera Clinical Site	Spartanburg29303	NCT07284979	Map
SC	Spartanburg Medical Research	Spartanburg29303	NCT07564414	Map
TN	Jackson Clinic	Jackson38305	NCT07564414	Map
TN	Holston Medical Group	Kingsport37660	NCT07564414	Map
TN	CNS Healthcare	Memphis38119	NCT07415954	Map
TN	CNS Healthcare	Memphis38119	NCT07564414	Map
TN	HealthStar Physicians, PC	Morristown37813	NCT07564414	Map
TN	Clinical Research Associates	Nashville37203	NCT07564414	Map
TN	Vanderbilt University Medical Center	Nashville37203	NCT05254314	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06338553	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT07221214	Map
TX	Amarillo Med Spec LLP	Amarillo79124	NCT07564414	Map
TX	Texas Diab & Endo, P.A.	Austin78731	NCT07564414	Map
TX	The University of Texas at Austin	Austin78723	NCT06173778	Map
TX	Velocity Clinical Research Austin	Austin78759	NCT07564414	Map
TX	Kailera Clinical Site	Brownsville78526	NCT07284979	Map
TX	UTHealth Clinical Research Unit (CRU) at UT Brownsville	Brownsville78520	NCT05119179	Map
TX	North Texas Endocrine Center	Dallas75231	NCT07564414	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT07361874	Map
TX	University of Texas Southwestern Medical Center	Dallas75390-9302	NCT07415954	Map
TX	Velocity Clin Res, Dallas	Dallas75230	NCT07564414	Map
TX	DM Clinical	Houston77065	NCT07253285	Map
TX	JCCT- Juno NW Houston	Houston77040	NCT07415954	Map
TX	JCCT- Juno NW Houston	Houston77040	NCT07564414	Map
TX	The Endocrine Center	Houston77079	NCT07564414	Map
TX	The University of Texas Health Science Center at Houston	Houston77054	NCT06173778	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT07227948	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT07325500	Map
TX	Sante Clinical Research	Kerrville78028	NCT07564414	Map
TX	Radiance Clinical Research	Lampasas76550	NCT07564414	Map
TX	Aeres Clinical Research	Laredo78041	NCT07564414	Map
TX	DCOL Ctr for Clin Res	Longview75605	NCT07564414	Map
TX	RGV Endocrine Center	McAllen78503	NCT07564414	Map
TX	AES San Antonio	San Antonio78229	NCT07564414	Map
TX	Kailera Clinical Site	San Antonio78229	NCT07284979	Map
TX	Northeast Clinical Research of San Antonio	San Antonio78233	NCT07564414	Map
TX	Quality Research Inc	San Antonio78209	NCT07564414	Map
TX	University Health - Texas Diabetic Institute	San Antonio78207	NCT06706284	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06706284	Map
TX	Consano Clinical Research, LLC	Shavano Park78231	NCT07415954	Map
TX	Consano Clinical Research, LLC	Shavano Park78231	NCT07564414	Map
TX	Mt Olympus Medical Research, LLC	Sugar Land77478	NCT07564414	Map
UT	J.Lewis Research Inc	Salt Lake City84109	NCT07564414	Map
UT	J.Lewis Research Inc	Salt Lake City84121	NCT07564414	Map
UT	University of Utah	Salt Lake City84108	NCT05173714	Map
UT	J.Lewis Research Inc	South Jordan84095	NCT07564414	Map
VA	Kailera Clinical Site	Manassas20110	NCT07284979	Map
VA	Health Res of Hampton Roads	Newport News23606	NCT07564414	Map
VA	Tidewater Physicians Multispecialty Group	Newport News23606	NCT07564414	Map
VA	Kailera Clinical Site	Richmond23236	NCT07284979	Map
VA	National Clin Res Inc.	Richmond23294	NCT07564414	Map
VA	Virginia Commonwealth University	Richmond23298	NCT05424003	Map
WA	University of Washington	Seattle98104	NCT05822609	Map
WA	University of Washington - Harborview Medical Center	Seattle98104	NCT05780905	Map
WA	University of Washington Medicine Diabetes Institute (UWMDI)	Seattle98109	NCT05819138	Map
WA	Providence Sacred Heart Medical Center	Spokane99204	NCT05822609	Map

Semaglutide clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	Total
Early P1	1								1	2
P1	10	2		86	2	1		1	2	104
P1/P2	3	1							1	5
P2	27	10	1	39	1	2		11	4	95
P2/P3	4	1		2		1		1	1	10
P3	19	15		81	1	4		13	5	138
P4	25	9	4	20	2	1	1	14	9	85
N/A	17	9	3	51	1	2		10	5	98

Recruiting Semaglutide clinical trials (164)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT05441267	ASCEND PLUSA Study of Cardiovascular Events iN Diabetes Plus	P4	Diabetes Mellitus, Type 2	20,000	Mar 2023
NCT06934655	Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth	P3	Pediatric Obesity	150	Jun 2026
NCT07253285	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	P3	Overweight	460	Jan 2026
NCT05501483	DiaSpaxAdipose Tissue Heterogeneity and Its Link to Type 2 Diabetes	N/A	Type 2 Diabetes	60	Feb 2023
NCT06977438	Promoting Healthy Children and Youth	P4	Obesity, Childhood	1,020	Jan 2027
NCT07135245	Improved Treatment and Monitoring of Alzheimer's Disease	P2	Alzheimer Disease (AD)	180	Jan 2026
NCT07021937	PLASTICBrain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity	P3	Obesity/Therapy	120	May 2026
NCT06015893	STARSemaglutide Therapy for Alcohol Reduction (STAR)	P2	Addiction	80	Oct 2023
NCT06975111	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	P2/P3	Menopause	200	Mar 2026
NCT07361874	IMPACT-MACSIMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	N/A	Mild Autonomous Cortisol Secretion (MACS)	75	Mar 2026
NCT07282613	REIMAGINEYOUNGA Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes	P3	Diabetes Mellitus, Type 2	80	Aug 2026
NCT07204249	GEMGlutide for Ending Methamphetamine	P2	Methamphetamine-dependence	162	Feb 2026
NCT07221214	GL1DER HIV RCTGLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	P2	HIV	200	Apr 2026
NCT07430332	GLP-1 RA for Stage 1 Type 1 Diabetes	P2	Stage 1 Diabetes Mellitus, Type 1	15	Sep 2027
NCT05569772	SERENASemaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes	P3	Glucose Intolerance After a Recent History of Gestational Diabetes	252	Sep 2023
NCT07091500	GLP-1Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity	N/A	Obesity	40	Aug 2025
NCT07254572	CASCADESAnti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	P4	Coronary Artery Disease	300	Jul 2025
NCT06082063	Steno1Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	P3	Cardiovascular Diseases	2,000	Jul 2024
NCT07325500	REINFORCEIncretin Microdosing for Cardiometabolic Health in People With HIV	P2	Weight Gain	30	Feb 2026
NCT07294950	RESTImpact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	P3	Obesity (Disorder)	98	Feb 2026
NCT07218354	CRAVECessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder	P3	Alcohol Use Disorder	622	Jul 2026
NCT07485062	MOTIVATEExercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes	P4	Type 2 Diabetes	164	May 2026
NCT07389941	SPICE-AFSemaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation	P4	Atrial Fibrillation (AF)	240	Oct 2026
NCT07547878	RAPID-CKDRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	P4	Chronic Kidney Disease	64	Apr 2026
NCT06706284	Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	P4	Spinal Cord Injuries	50	Apr 2025
NCT07227948	Repurposing Semaglutide for the Treatment of Cocaine Use Disorder	P2	Cocaine Use Disorder	75	Jan 2026
NCT07213466	OBOE-MayoIndividualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	P4	Bipolar I Disorder	100	Jan 2026
NCT07400107	AMAZE 8AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	P3	Obesity	1,000	May 2026
NCT07391267	MAFLDPathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.	N/A	Chronic Kidney Diseases	90	Feb 2026
NCT07302802	Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice	—	Monogenic Obesity	70	Dec 2025
NCT07200622	Oral Semaglutide in Patients With Alzheimer's Disease	P2	Alzheimer Disease	60	Sep 2025
NCT06792422	ABSALONA Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma	P4	Primary Open Angle Glaucoma (POAG)	126	Jan 2025
NCT07275697	WAITWaiting on Atrial Fibrillation Intervention Therapy (WAIT) Study	P4	Atrial Fibrillation (AF)	200	Dec 2025
NCT06072963	COMMETS- Combination MCI Metabolic Syndrome	P2	Alzheimer Disease	80	Jan 2024
NCT07428746	GLOWInvestigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes	P3	Diabetes Mellitus, Type 2	20	Apr 2026
NCT06762314	Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	P2	Diabetes	105	Jan 2025
NCT05305794	TOLEDDOEffect of Weekly GLP1 Agonist Treatment in "Double Diabetes"	P3	Double Diabetes	76	Jul 2022
NCT07055607	PILLARA Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice	—	Obesity	1,250	May 2025
NCT07073053	The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms	P4	Glucagon-Like Peptide-1 Receptor Agonists	60	Oct 2025
NCT07065383	Re-CHARMRebalancing the Fat Content of the Heart and Muscles	N/A	Diabetes Mellitus Type 2	60	Aug 2025
NCT07511543	LEASTGlucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy	P2	Ischemic Stroke	100	Jun 2026
NCT07317115	MAGvMEDSide-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes	N/A	Obesity (Disorder)	20	Mar 2026
NCT06909006	OBES1TYSemaglutide Treatment in Type 1 Diabetes	P3	Obesity in Diabetes	122	Oct 2025
NCT07239570	CKD-bioMatchA Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	P4	Chronic Kidney Disease(CKD)	125	Jun 2025
NCT06499857	SEMINAL-AFSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation	P3	Overweight or Obesity	200	Apr 2025
NCT06411210	Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment	P2	Diabetes type1	54	Jul 2024
NCT06986993	ONSETImpact of Semaglutide on Tobacco Use and Related Health Behaviors	P4	Tobacco Use	40	Jul 2024
NCT05819853	RESTORERole of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome	P3	PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries	80	Nov 2023
NCT07527195	RASMUSUnderstanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)	P1	Obesity	100	Apr 2026
NCT07010432	RAMBOThe Role of the Amylin Analogue Cagrilintide in Bone Metabolism	P1	Obesity	144	Jun 2025
NCT07523633	HASHTAGEffect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	P2	Cannabis Use Disorder	100	Apr 2026
NCT07483801	DECODEDECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	P4	Cardiovascular Diseases	112	Mar 2026
NCT07564414	A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	P3	Obesity	2,500	May 2026
NCT07284979	Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	P3	Obesity	1,200	Dec 2025
NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	P2	Prostate Carcinoma	60	Jan 2026
NCT05938712	HALLMARKThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients	P2	Kidney Transplant Recipients	20	Oct 2023
NCT06788626	GALLOP2Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	P3	Acute Ischemic Stroke	390	Feb 2025
NCT07030621	STARSEfficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial	P3	Acute Ischemic Stroke	436	Jul 2025
NCT07446998	PLATEAUProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	P2	Obesity & Overweight	200	Mar 2026
NCT06852391	JOULE-MARSJOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity	P4	Obesity (Disorder)	74	Jun 2025
NCT06825793	Semaglutide's Weight Loss Effects in Obesity	N/A	Obesity	56	Feb 2025
NCT06613854	E-SEMPAEffect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes	P4	Type 2 Diabetes Mellitus (T2DM)	90	Oct 2024
NCT05702931	Sema-RTxSemaglutide Treatment for Hyperglycaemia After Renal Transplantation	P4	Hyperglycemia	104	Sep 2024
NCT06461377	The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy	P4	Type 2 Diabetes	50	Jun 2024
NCT05822609	RT1DTrial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes	P2	Diabetic Kidney Disease	60	Apr 2024
NCT05630586	ASSETAcute Subcutaneous SemaglutidE in Acute Ischemic sTroke	P2	Acute Ischemic Stroke	380	Apr 2023
NCT05071898	PORTPharmacogenetics of Response to GLP1R Agonists	P1	Obesity	600	Apr 2022
NCT05746039	Feasibility of Semaglutide in Advanced Lung Disease	P1/P2	Obesity	8	Jan 2024
NCT05819138	T1-DISCOType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes	P3	Diabetes Mellitus, Type 1	60	Jun 2023
NCT06913023	SPOT-DMSemaglutide for the Prevention Of Post-Transplant Diabetes Mellitus	P2/P3	Kidney Transplant Recipient	74	Jan 2026
NCT07280221	WEgovy Real World Assessment of Weight Loss in Korea	—	Obesity	500	Nov 2025
NCT07184086	A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet	P1	Obesity	80	Sep 2025
NCT07415954	A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes	P2	Diabetes Mellitus, Type 2	270	Apr 2026
NCT06575738	PRESSUREPhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	P1	Obesity	40	Oct 2024
NCT07136714	SEMAMOODDoes Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity	P4	Major Depressive Disorder	116	Sep 2025
NCT07017270	GUARD-1Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	P4	Kidney Disease, Chronic	100	Jul 2025
NCT07411378	OBATesting the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.	P2	Muscle Wasting	164	Jul 2026
NCT07059377	GLP1-SCSemaglutide for Smoking Cessation in Patients With Diabetes	P3	Diabetes Mellitus, Type 2	100	Feb 2026
NCT04174755	SWIFTSemaglutide's Efficacy in Achieving Weight Loss for Those With HIV	N/A	Obesity	80	Jun 2022
NCT07466017	A Study of CS060380 Tablets in Patients With MASH and Obesity	P2	Metabolic Dysfunction-associated Steatohepatitis (MASH)	120	Apr 2026
NCT07040592	HARPOff-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide	P2	Alcohol Use Disorder (AUD)	30	Jan 2026
NCT07150975	Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects	P3	Obesity/Overweight in Adult	420	Sep 2025
NCT07293325	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	N/A	Adults With Simple Obesity	66	Jun 2025
NCT06318442	The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes	N/A	Steroid-Induced Diabetes	60	May 2024
NCT05689372	Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	—	Diabetes Mellitus, Type 2	600	Feb 2026
NCT07242534	SEQEffect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.	P4	Infertility	62	Jan 2026
NCT06954090	SIGNALUrinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	P4	Type 2 DM	50	Nov 2025
NCT06003153	GLUCOSE-MGHGLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH	P4	Genetic Predisposition	125	Mar 2024
NCT06836284	The Evira Study: Additional Support During Obesity Treatment	N/A	Childhood Obesity	40	Feb 2026
NCT06184633	DUTCH-WAISTDUTCH Weight Control in Atrial Fibrillation Study	P4	Atrial Fibrillation	280	Jul 2024
NCT06546384	GLP-1 RAGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease	N/A	Adiposity	64	May 2026
NCT05586802	KLIN-HEALTHSex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome	P3	Klinefelter Syndrome	150	Mar 2023
NCT07509112	SHIFTSemaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study	P2	Methamphetamine Use Disorder	40	May 2026
NCT07297589	EPIC-CTEpicardial Cardiac Fat-CT (EPIC-CT)	P3	STEMI - ST Elevation Myocardial Infarction	136	Dec 2025
NCT06691243	STACEvaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV	P2	Cocaine Use Disorder	40	Aug 2025
NCT07101939	PROACTA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)	P2	Obesity	120	Jun 2025
NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	P4	Obesity	30	May 2025
NCT06338553	GLP-TEPGLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab	Early P1	Type 1 Diabetes	24	Jun 2024
NCT05173714	SLIMMSit Less, Interact and Move More (SLIMM) 2 Study	P2	Chronic Kidney Diseases	156	Dec 2021
NCT07314684	STABLE-GLP1GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM	P4	T2DM (Type 2 Diabetes Mellitus)	80	Sep 2025
NCT07282769	Semaglutide (Wegovy) Treatment for Trichotillomania	P2	Trichotillomania (Hair-Pulling Disorder)	10	Jun 2026
NCT07401992	SEMAPSOEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis	P4	Psoriasis (PsO)	62	Jan 2026
NCT06449625	PROTECTSemaglutide in Auto-HSCT	P2	Intestinal Mucositis	40	Aug 2024
NCT06894784	SEMPAA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes	P3	Diabetes Type 1	36	Apr 2025
NCT06937060	SEMPSOEffect of Semaglutide in Patients With Psoriasis and Obesity	P3	Psoriasis (PsO)	14	Mar 2025
NCT06387199	SEMA SMAAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide	P2/P3	Type 1 Diabetes	26	Dec 2024
NCT07179120	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	P2	Obesity-related Male Infertility	180	May 2026
NCT07251556	GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis	P4	Psoriasis Arthritis	40	Dec 2025
NCT05202353	A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver	P1	Obesity	30	Oct 2024
NCT07570810	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	N/A	Type 2 Diabetes	30	Jun 2026
NCT07187856	Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus	P2	Type 2 Diabetes Mellitus (T2DM)	80	Jan 2026
NCT07319975	Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	N/A	Obesity	48	Dec 2025
NCT07165158	The Effect of Semaglutide on Bone Health	P4	Osteoporosis	150	Sep 2025
NCT07139548	A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes	P3	T2DM	600	Aug 2025
NCT06989203	Protein Supplementation Intervention on Body Weight	N/A	Obesity	140	Jun 2025
NCT06989177	Probiotic Intervention on Body Weight	N/A	Obesity	140	Jun 2025
NCT05780905	Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes	P4	Diabetes Mellitus, Type 2	50	Jan 2024
NCT06959784	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)	P4	Diabetes Mellitus	142	Jan 2024
NCT05195944	Semaglutide vs Sitagliptin	P4	Liver Transplant; Complications	58	Oct 2022
NCT05254314	GATA-3Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)	P2	Asthma	100	Oct 2022
NCT06423599	FIT-HFEffect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	P2/P3	Heart Failure With Reduced Ejection Fraction	100	May 2024
NCT07513168	Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults	P4	Obesity	60	Aug 2025
NCT06982859	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	P1	Diabetes Mellitus	95	Jun 2025
NCT06548490	GLP-1R Agonist Treatment for Opioid Use Disorder	P2	Opioid Use Disorder	200	Jan 2025
NCT07505303	MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial	P2	Adult Obesity	160	Mar 2026
NCT06716216	A Study of BGM0504 in Participants with Type 2 Diabetes	P3	Type 2 Diabetes Mellitus (T2DM)	537	Nov 2024
NCT07223983	SEMASemaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	P1	Alcohol Use Disorder	10	Mar 2026
NCT06616961	Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus	P3	Obesity	480	Nov 2024
NCT05119179	Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes	P4	PreDiabetes	300	Nov 2021
NCT05714683	Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	—	Diabetes Mellitus, Type 2	600	Dec 2025
NCT06633783	A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®	P3	Obesity	370	Oct 2024
NCT03884075	NAFLD HEROESNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	P2	Non-Alcoholic Steatohepatitis	84	Jul 2019
NCT07430059	SLIM-1Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant	P1	Obesity & Overweight	20	Apr 2026
NCT07195994	A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes	N/A	Prediabetes / Type 2 Diabetes	90	Feb 2026
NCT07295223	GALACTUSEffect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)	P3	Acute Myocardial Infarction With ST Elevation	44	Dec 2025
NCT06287307	SEABARSemaglutide 2.4mg for Low Responders After Bariatric Surgery	P4	Obesity	152	May 2024
NCT06717698	A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease	P2	Chronic Kidney Disease	465	Dec 2024
NCT06557811	SemaFatCardEffect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction	P4	Diabetic Patients	88	Sep 2024
NCT06639464	SHORESemaglutide for Helping Opioid Recovery	P2	Opioid Use Disorder	46	Jun 2025
NCT07374328	TREDTriple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus	P1/P2	Type 2 Diabetes	240	Jun 2025
NCT06738979	A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects	P3	Obesity	408	Mar 2025
NCT05371496	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	P2	Cardiomyopathy	81	Sep 2022
NCT07465965	A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults	P1	Overweight	60	Mar 2026
NCT07554417	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	P4	GLP - 1	20	Apr 2026
NCT07323134	The Effect of Semaglutide on the Intestinal Flora in Obesity	—	Obesity	40	Feb 2026
NCT06173778	Semaglutide for Post-Smoking Cessation Weight Management	P2	Obesity	197	Apr 2024
NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	P2	NAFLD	50	Feb 2024
NCT07064486	A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia	P3	Type 2 Diabetes (T2DM)	477	Jul 2025
NCT06908694	GAINPCCONTROLInvestigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy	P4	Prostate Cancer	20	Jul 2025
NCT06410352	Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome	P4	Metabolic Syndrome	220	Mar 2024
NCT07225816	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	P1	Obesity	75	Nov 2025
NCT07272343	The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes	P4	Type 2 Diabetes Mellitus (T2DM)	100	Feb 2023
NCT07424430	SEMA-CKMReal-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes	—	Diabetes (DM)	400	Mar 2026
NCT06764056	METAfoieCharacterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)	N/A	Metabolic Associated Fatty Liver Disease	120	Jan 2025
NCT06269120	SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary	—	Type 2 Diabetes	470	Sep 2024
NCT04873050	SWEETTreatment to Regress to Normoglycemia in Women with a Recent History of GDM	P4	Pre Diabetes	102	Jan 2022
NCT06396416	Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2	P4	Obesity	60	Sep 2024
NCT05419726	Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.	—	Obesity	20	Feb 2023
NCT06896981	Semaglutide in Women With Polycystic Ovary Syndrome and Obesity	P2/P3	Polycystic Ovary Syndrome (PCOS) Women	30	Feb 2025
NCT05340868	GAROSGenetics of the Acute Response to Oral Semaglutide	N/A	PreDiabetes	1,000	Sep 2022
NCT06060392	Sema-LitEffect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus	N/A	Liver Transplant; Complications	50	Oct 2023
NCT06541509	SEMAHEARTMechanisms of Semaglutide Therapy in Heart Failure Patients	P1/P2	Heart Failure	10	Jul 2024
NCT06555146	Sema-RMASemaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy	N/A	Diabetes Mellitus, Type 2	15	Aug 2024
NCT06863363	PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults	P4	Non-diabetic Obesity	212	—

Semaglutide clinical trials by indication

Diabetes Mellitus, Type 2 (100)

NCT	Acronym	Phase	Status	Title
NCT05441267	ASCEND PLUS	P4	recruiting	A Study of Cardiovascular Events iN Diabetes Plus
NCT07282613	REIMAGINEYOUNG	P3	not yet recruiting	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07428746	GLOW	P3	not yet recruiting	Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
NCT03811561	FOCUS	P3	active not recruiting	A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT07415954	—	P2	recruiting	A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07059377	GLP1-SC	P3	recruiting	Semaglutide for Smoking Cessation in Patients With Diabetes
NCT05689372	—	N/A	enrolling by invitation	Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
NCT06083675	—	P3	withdrawn	Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
+ 92 more, see All trials below.

Obesity (75)

NCT	Acronym	Phase	Status	Title
NCT06571383	—	P4	active not recruiting	STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT07091500	GLP-1	N/A	recruiting	Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
NCT07400107	AMAZE 8	P3	not yet recruiting	AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT06814938	—	P4	active not recruiting	A Study of a Novel Precision Medicine Approach For Obesity
NCT06780449	—	P3	active not recruiting	A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT07011667	—	P3	active not recruiting	A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07055607	PILLAR	N/A	enrolling by invitation	A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
NCT07527195	RASMUS	P1	recruiting	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
+ 67 more, see All trials below.

Diabetes (65)

NCT	Acronym	Phase	Status	Title
NCT06762314	—	P2	recruiting	Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT05990374	—	N/A	unknown	Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
NCT05768945	DREAM	N/A	completed	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
NCT03061214	SUSTAIN	P3	completed	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
NCT02849080	PIONEER 7	P3	completed	Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
NCT03136484	SUSTAIN 8	P3	completed	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
NCT02773381	—	P1	completed	A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
NCT02692716	PIONEER 6	P3	completed	A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
+ 57 more, see All trials below.

Type 2 Diabetes (33)

NCT	Acronym	Phase	Status	Title
NCT05501483	DiaSpax	N/A	recruiting	Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
NCT07485062	MOTIVATE	P4	not yet recruiting	Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
NCT06042153	—	P4	active not recruiting	DIALYSIS-TIR Study
NCT06461377	—	P4	recruiting	The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
NCT06050577	—	P2	active not recruiting	The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial
NCT07570810	—	N/A	not yet recruiting	Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
NCT06980623	—	N/A	active not recruiting	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
NCT06649344	—	P3	active not recruiting	A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
+ 25 more, see All trials below.

Overweight (19)

NCT	Acronym	Phase	Status	Title
NCT07253285	—	P3	recruiting	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT06884293	—	P3	active not recruiting	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
NCT07465965	—	P1	recruiting	A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
NCT06267092	—	P1	completed	A Study of How CagriSema Works on Appetite in People With Excess Body Weight
NCT06041217	STEP12	P3	completed	A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
NCT05394519	REDEFINE 2	P3	completed	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05890976	OASIS 3	P3	completed	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
NCT05564117	OASIS 4	P3	completed	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
+ 11 more, see All trials below.

Healthy Volunteers (10)

NCT	Acronym	Phase	Status	Title
NCT05227196	—	P1	completed	A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
NCT05129891	—	P1	completed	A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
NCT05429593	—	P1	completed	A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
NCT04259801	—	P1	completed	First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
NCT04016974	—	P1	completed	A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
NCT04109508	C	P1	completed	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
NCT04097600	D	P1	completed	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
NCT04228354	—	P1	completed	A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
+ 2 more, see All trials below.

Type 2 Diabetes Mellitus (7)

NCT	Acronym	Phase	Status	Title
NCT05067621	—	P2	active not recruiting	Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT07112872	—	P2	active not recruiting	A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT06065540	REIMAGINE 2	P3	completed	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06339086	—	P3	unknown	Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
NCT06161844	HD1916	P3	completed	Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
NCT06489457	SEMAT	P3	completed	The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
NCT04515849	—	P2	completed	A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM) (6)

NCT	Acronym	Phase	Status	Title
NCT06613854	E-SEMPA	P4	recruiting	Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
NCT07187856	—	P2	not yet recruiting	Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
NCT06778967	Optimum 2	P3	active not recruiting	A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
NCT06716216	—	P3	recruiting	A Study of BGM0504 in Participants with Type 2 Diabetes
NCT07272343	—	P4	recruiting	The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
NCT07163624	T2DM	P2	completed	UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

Alcohol Use Disorder (5)

NCT	Acronym	Phase	Status	Title
NCT07218354	CRAVE	P3	not yet recruiting	Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
NCT07223983	SEMA	P1	recruiting	Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
NCT05892432	AUD	P2	completed	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
NCT05891587	STAR-T	P2	completed	Semaglutide Therapy for Alcohol Reduction - Tulsa
NCT05520775	—	P2	completed	Semaglutide for Alcohol Use Disorder

Type 1 Diabetes (5)

NCT	Acronym	Phase	Status	Title
NCT06338553	GLP-TEP	Early P1	recruiting	GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
NCT06387199	SEMA SMA	P2/P3	recruiting	Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
NCT06057077	—	P1/P2	unknown	Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus
NCT05537233	ADJUST-T1D	P2	completed	ADJUnct Semaglutide Treatment in Type 1 Diabetes
NCT05390307	OTID	N/A	completed	Obesity Treatment to Improve Diabetes

Diabetes Mellitus Type 2 (4)

NCT	Acronym	Phase	Status	Title
NCT07065383	Re-CHARM	N/A	recruiting	Rebalancing the Fat Content of the Heart and Muscles
NCT06851962	EPHIC-DIA2	P4	active not recruiting	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT07056803	—	N/A	completed	Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus
NCT06629688	—	N/A	completed	Semaglutide and Intestinal Iron Absorption

Non-alcoholic Steatohepatitis (4)

NCT	Acronym	Phase	Status	Title
NCT04822181	ESSENCE	P3	active not recruiting	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT05016882	NASH	P2	completed	Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT05766709	—	P1	completed	A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
NCT03987451	—	P2	completed	A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Obesity & Overweight (3)

NCT	Acronym	Phase	Status	Title
NCT07446998	PLATEAU	P2	recruiting	Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07430059	SLIM-1	P1	not yet recruiting	Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
NCT04940078	—	P1	completed	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Chronic Kidney Disease (3)

NCT	Acronym	Phase	Status	Title
NCT07547878	RAPID-CKD	P4	not yet recruiting	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT06717698	—	P2	recruiting	A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06131372	—	P2	completed	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Obesity (Disorder) (3)

NCT	Acronym	Phase	Status	Title
NCT07294950	REST	P3	recruiting	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
NCT07317115	MAGvMED	N/A	recruiting	Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
NCT06852391	JOULE-MARS	P4	recruiting	JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Acute Ischemic Stroke (3)

NCT	Acronym	Phase	Status	Title
NCT06788626	GALLOP2	P3	not yet recruiting	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
NCT07030621	STARS	P3	not yet recruiting	Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
NCT05630586	ASSET	P2	recruiting	Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

Overweight and Obesity (3)

NCT	Acronym	Phase	Status	Title
NCT05670379	LIBERATE-1	P1	completed	Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
NCT06500429	GLP-1	P2	completed	A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT05132088	OASIS 2	P3	completed	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

Healthy Volunteers Type 2 Diabetes (3)

NCT	Acronym	Phase	Status	Title
NCT06642584	—	P1	completed	A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV
NCT04878406	—	P1	completed	A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
NCT04513704	—	P1	completed	A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times

Atrial Fibrillation (3)

NCT	Acronym	Phase	Status	Title
NCT05209165	—	P4	suspended	Semaglutide to Reduce Atrial Fibrillation Burden
NCT06184633	DUTCH-WAIST	P4	recruiting	DUTCH Weight Control in Atrial Fibrillation Study
NCT04885634	SOCRATES-AF	P3	withdrawn	Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

Healthy (3)

NCT	Acronym	Phase	Status	Title
NCT05751226	—	P1	completed	A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
NCT06699329	MK-0616	P1	completed	A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
NCT04865744	—	P4	completed	The Effect of Semaglutide on Pituitary Function

Healthy Participants (3)

NCT	Acronym	Phase	Status	Title
NCT05996874	—	P1	completed	A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants
NCT05784402	—	P1	completed	A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
NCT06097390	—	P1	completed	A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Metabolism and Nutrition Disorder (3)

NCT	Acronym	Phase	Status	Title
NCT03548935	STEP 1	P3	completed	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548987	STEP 4	P3	completed	Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT02453711	—	P2	completed	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Obesity, Childhood (2)

NCT	Acronym	Phase	Status	Title
NCT06977438	—	P4	not yet recruiting	Promoting Healthy Children and Youth
NCT04873245	QUEST	P2	active not recruiting	Lifestyle Counseling and Medication for Adolescent Weight Management

Atrial Fibrillation (AF) (2)

NCT	Acronym	Phase	Status	Title
NCT07389941	SPICE-AF	P4	not yet recruiting	Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
NCT07275697	WAIT	P4	not yet recruiting	Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

Cardiovascular Diseases (2)

NCT	Acronym	Phase	Status	Title
NCT06082063	Steno1	P3	recruiting	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
NCT07483801	DECODE	P4	not yet recruiting	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Polycystic Ovary Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT06222437	—	P1	withdrawn	Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
NCT05646199	PCOS	P2/P3	unknown	Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

Chronic Kidney Diseases (2)

NCT	Acronym	Phase	Status	Title
NCT07391267	MAFLD	N/A	not yet recruiting	Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
NCT05173714	SLIMM	P2	recruiting	Sit Less, Interact and Move More (SLIMM) 2 Study

Cocaine Use Disorder (2)

NCT	Acronym	Phase	Status	Title
NCT07227948	—	P2	recruiting	Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
NCT06691243	STAC	P2	recruiting	Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

Psoriasis (PsO) (2)

NCT	Acronym	Phase	Status	Title
NCT07401992	SEMAPSO	P4	recruiting	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
NCT06937060	SEMPSO	P3	recruiting	Effect of Semaglutide in Patients With Psoriasis and Obesity

Alzheimer Disease (2)

NCT	Acronym	Phase	Status	Title
NCT07200622	—	P2	not yet recruiting	Oral Semaglutide in Patients With Alzheimer's Disease
NCT06072963	—	P2	recruiting	COMMETS- Combination MCI Metabolic Syndrome

Major Depressive Disorder (2)

NCT	Acronym	Phase	Status	Title
NCT07136714	SEMAMOOD	P4	recruiting	Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
NCT04466345	—	P2	completed	Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Diabetes Mellitus, Type 1 (2)

NCT	Acronym	Phase	Status	Title
NCT05819138	T1-DISCO	P3	recruiting	Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
NCT07087795	—	P1	active not recruiting	A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

Diabetes Mellitus (2)

NCT	Acronym	Phase	Status	Title
NCT06959784	—	P4	enrolling by invitation	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06982859	—	P1	recruiting	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Opioid Use Disorder (2)

NCT	Acronym	Phase	Status	Title
NCT06548490	—	P2	recruiting	GLP-1R Agonist Treatment for Opioid Use Disorder
NCT06639464	SHORE	P2	recruiting	Semaglutide for Helping Opioid Recovery

Spinal Cord Injuries (2)

NCT	Acronym	Phase	Status	Title
NCT06706284	—	P4	recruiting	Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
NCT03292315	—	P4	completed	Once Weekly GLP-1 in Persons With Spinal Cord Injury

Obesity and Obesity-related Medical Conditions (2)

NCT	Acronym	Phase	Status	Title
NCT06754163	STEP@STAH	P4	active not recruiting	Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
NCT06803888	—	P4	active not recruiting	Bariatric Surgery vs. Semaglutide vs. Tirzepatide

Idiopathic Intracranial Hypertension (2)

NCT	Acronym	Phase	Status	Title
NCT06027567	IIH:DUAL	P4	completed	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
NCT06361823	—	P3	unknown	Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

Diabetic Kidney Disease (2)

NCT	Acronym	Phase	Status	Title
NCT05822609	RT1D	P2	recruiting	Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05897372	WP3	P2	terminated	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

Metabolic Disease (2)

NCT	Acronym	Phase	Status	Title
NCT07457424	DIGRAT	N/A	active not recruiting	Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
NCT07043361	Semaglutide	N/A	completed	Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Liver Transplant; Complications (2)

NCT	Acronym	Phase	Status	Title
NCT05195944	—	P4	enrolling by invitation	Semaglutide vs Sitagliptin
NCT06060392	Sema-Lit	N/A	recruiting	Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

Obesity or Overweight (2)

NCT	Acronym	Phase	Status	Title
NCT05813925	—	P3	completed	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
NCT05996848	REDEFINE 6	P3	completed	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Obesity and Overweight (2)

NCT	Acronym	Phase	Status	Title
NCT06827002	—	P1/P2	active not recruiting	Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
NCT03707990	—	P1	completed	A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

PreDiabetes (2)

NCT	Acronym	Phase	Status	Title
NCT05119179	—	P4	recruiting	Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
NCT05340868	GAROS	N/A	recruiting	Genetics of the Acute Response to Oral Semaglutide

Type2 Diabetes (2)

NCT	Acronym	Phase	Status	Title
NCT04451837	—	P2	active not recruiting	Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
NCT04854083	MitoSema	P4	unknown	Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

Nonalcoholic Steatohepatitis (2)

NCT	Acronym	Phase	Status	Title
NCT04971785	WAYFIND	P2	completed	Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT03987074	NASH	P2	completed	Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

PCOS (2)

NCT	Acronym	Phase	Status	Title
NCT03919929	TEAL	P2/P3	completed	Treating PCOS With Semaglutide vs Active Lifestyle Intervention
NCT04263415	—	P4	completed	The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 (2)

NCT	Acronym	Phase	Status	Title
NCT04143945	—	P2	completed	A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
NCT04007107	—	P2	completed	A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Hepatobiliary Disorders (2)

NCT	Acronym	Phase	Status	Title
NCT03357380	—	P1	completed	A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
NCT02970942	—	P2	completed	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Stage 1 Diabetes Mellitus, Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT07430332	—	P2	not yet recruiting	GLP-1 RA for Stage 1 Type 1 Diabetes

Muscle Wasting (1)

NCT	Acronym	Phase	Status	Title
NCT07411378	OBA	P2	not yet recruiting	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Ischemic Stroke (1)

NCT	Acronym	Phase	Status	Title
NCT07511543	LEAST	P2	not yet recruiting	Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

Pediatric Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06934655	—	P3	not yet recruiting	Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

Methamphetamine Use Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT07509112	SHIFT	P2	not yet recruiting	Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Trichotillomania (Hair-Pulling Disorder) (1)

NCT	Acronym	Phase	Status	Title
NCT07282769	—	P2	not yet recruiting	Semaglutide (Wegovy) Treatment for Trichotillomania

Adiposity (1)

NCT	Acronym	Phase	Status	Title
NCT06546384	GLP-1 RA	N/A	not yet recruiting	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

Obesity/Therapy (1)

NCT	Acronym	Phase	Status	Title
NCT07021937	PLASTIC	P3	not yet recruiting	Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Obesity-related Male Infertility (1)

NCT	Acronym	Phase	Status	Title
NCT07179120	—	P2	not yet recruiting	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

Cannabis Use Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT07523633	HASHTAG	P2	recruiting	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

HIV (1)

NCT	Acronym	Phase	Status	Title
NCT07221214	GL1DER HIV RCT	P2	recruiting	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

GLP - 1 (1)

NCT	Acronym	Phase	Status	Title
NCT07554417	—	P4	not yet recruiting	Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

Metabolic Dysfunction-associated Steatohepatitis (MASH) (1)

NCT	Acronym	Phase	Status	Title
NCT07466017	—	P2	recruiting	A Study of CS060380 Tablets in Patients With MASH and Obesity

Diabetes (DM) (1)

NCT	Acronym	Phase	Status	Title
NCT07424430	SEMA-CKM	N/A	not yet recruiting	Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Adult Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT07505303	—	P2	not yet recruiting	MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Mild Autonomous Cortisol Secretion (MACS) (1)

NCT	Acronym	Phase	Status	Title
NCT07361874	IMPACT-MACS	N/A	recruiting	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

Menopause (1)

NCT	Acronym	Phase	Status	Title
NCT06975111	—	P2/P3	recruiting	Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Childhood Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06836284	—	N/A	recruiting	The Evira Study: Additional Support During Obesity Treatment

Weight Gain (1)

NCT	Acronym	Phase	Status	Title
NCT07325500	REINFORCE	P2	recruiting	Incretin Microdosing for Cardiometabolic Health in People With HIV

Prediabetes / Type 2 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT07195994	—	N/A	recruiting	A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07202247	—	P2	recruiting	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Bipolar I Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT07213466	OBOE-Mayo	P4	recruiting	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Infertility (1)

NCT	Acronym	Phase	Status	Title
NCT07242534	SEQ	P4	recruiting	Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

Alcohol Use Disorder (AUD) (1)

NCT	Acronym	Phase	Status	Title
NCT07040592	HARP	P2	recruiting	Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Methamphetamine-dependence (1)

NCT	Acronym	Phase	Status	Title
NCT07204249	GEM	P2	recruiting	Glutide for Ending Methamphetamine

Kidney Transplant Recipient (1)

NCT	Acronym	Phase	Status	Title
NCT06913023	SPOT-DM	P2/P3	not yet recruiting	Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Alzheimer Disease (AD) (1)

NCT	Acronym	Phase	Status	Title
NCT07135245	—	P2	not yet recruiting	Improved Treatment and Monitoring of Alzheimer's Disease

Acute Myocardial Infarction With ST Elevation (1)

NCT	Acronym	Phase	Status	Title
NCT07295223	GALACTUS	P3	recruiting	Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

STEMI - ST Elevation Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT07297589	EPIC-CT	P3	recruiting	Epicardial Cardiac Fat-CT (EPIC-CT)

Psoriasis Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT07251556	—	P4	not yet recruiting	GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

Monogenic Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT07302802	—	N/A	recruiting	Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Type 2 DM (1)

NCT	Acronym	Phase	Status	Title
NCT06954090	SIGNAL	P4	enrolling by invitation	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Obesity in Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06909006	OBES1TY	P3	not yet recruiting	Semaglutide Treatment in Type 1 Diabetes

Glucagon-Like Peptide-1 Receptor Agonists (1)

NCT	Acronym	Phase	Status	Title
NCT07073053	—	P4	not yet recruiting	The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

Obesity/Overweight in Adult (1)

NCT	Acronym	Phase	Status	Title
NCT07150975	—	P3	recruiting	Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Osteoporosis (1)

NCT	Acronym	Phase	Status	Title
NCT07165158	—	P4	not yet recruiting	The Effect of Semaglutide on Bone Health

T2DM (Type 2 Diabetes Mellitus) (1)

NCT	Acronym	Phase	Status	Title
NCT07314684	STABLE-GLP1	P4	recruiting	GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

T2DM (1)

NCT	Acronym	Phase	Status	Title
NCT07139548	—	P3	not yet recruiting	A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Kidney Disease, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT07017270	GUARD-1	P4	not yet recruiting	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Coronary Artery Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07254572	CASCADES	P4	recruiting	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

Type 2 Diabetes (T2DM) (1)

NCT	Acronym	Phase	Status	Title
NCT07064486	—	P3	recruiting	A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06908694	GAINPCCONTROL	P4	recruiting	Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Chronic Kidney Disease(CKD) (1)

NCT	Acronym	Phase	Status	Title
NCT07239570	CKD-bioMatch	P4	recruiting	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Adults With Simple Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT07293325	—	N/A	recruiting	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Diabetes Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT06894784	SEMPA	P3	recruiting	A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

Chronic Weight Management (1)

NCT	Acronym	Phase	Status	Title
NCT06972992	—	P1	completed	A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

Overweight or Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06499857	SEMINAL-AF	P3	recruiting	Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Endometrial Hyperplasia (1)

NCT	Acronym	Phase	Status	Title
NCT05829460	—	P2	withdrawn	Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Polycystic Ovary Syndrome (PCOS) Women (1)

NCT	Acronym	Phase	Status	Title
NCT06896981	—	P2/P3	recruiting	Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

Metabolic Associated Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06764056	METAfoie	N/A	not yet recruiting	Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Primary Open Angle Glaucoma (POAG) (1)

NCT	Acronym	Phase	Status	Title
NCT06792422	ABSALON	P4	recruiting	A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

Healthy Volunteer Study (1)

NCT	Acronym	Phase	Status	Title
NCT06608433	PIANO	N/A	completed	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

Sleep Apnea Syndrome (OSAS) (1)

NCT	Acronym	Phase	Status	Title
NCT07281196	—	N/A	completed	Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

Type2diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06648031	DehydraTECH	P1	completed	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Weight Management (1)

NCT	Acronym	Phase	Status	Title
NCT06604624	—	P3	completed	Semaglutide in Treatment of Obesity

Hyperglycemia (1)

NCT	Acronym	Phase	Status	Title
NCT05702931	Sema-RTx	P4	recruiting	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

Diabetic Patients (1)

NCT	Acronym	Phase	Status	Title
NCT06557811	SemaFatCard	P4	not yet recruiting	Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

Intestinal Mucositis (1)

NCT	Acronym	Phase	Status	Title
NCT06449625	PROTECT	P2	not yet recruiting	Semaglutide in Auto-HSCT

Diabetes type1 (1)

NCT	Acronym	Phase	Status	Title
NCT06411210	—	P2	recruiting	Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT06541509	SEMAHEART	P1/P2	recruiting	Mechanisms of Semaglutide Therapy in Heart Failure Patients

Tobacco Use (1)

NCT	Acronym	Phase	Status	Title
NCT06986993	ONSET	P4	recruiting	Impact of Semaglutide on Tobacco Use and Related Health Behaviors

Cognitive Change (1)

NCT	Acronym	Phase	Status	Title
NCT06363487	OxSENSE	N/A	completed	Semaglutide and Cognition in Healthy Volunteers

Alcohol-related Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06409130	—	P2	completed	Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Heart Failure With Reduced Ejection Fraction (1)

NCT	Acronym	Phase	Status	Title
NCT06423599	FIT-HF	P2/P3	recruiting	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure

Steroid-Induced Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06318442	—	N/A	recruiting	The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes

Muscle Loss (1)

NCT	Acronym	Phase	Status	Title
NCT06282458	QUALITY	P2	completed	Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Obesity; Drug (1)

NCT	Acronym	Phase	Status	Title
NCT06390501	—	N/A	completed	The Effect of Weekly Semaglutide Treatment on Energy Expenditure

Genetic Predisposition (1)

NCT	Acronym	Phase	Status	Title
NCT06003153	GLUCOSE-MGH	P4	recruiting	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

Metabolic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06410352	—	P4	recruiting	Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Scleroderma, Systemic (1)

NCT	Acronym	Phase	Status	Title
NCT06149260	—	P1	unknown	Subcutaneous Semaglutide in Systemic Scleroderma

NAFLD (1)

NCT	Acronym	Phase	Status	Title
NCT05424003	—	P2	recruiting	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Obesity Morbid (1)

NCT	Acronym	Phase	Status	Title
NCT06234111	—	N/A	active not recruiting	Semaglutide and Physical Activity for Obesity and Multimorbidity

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries (1)

NCT	Acronym	Phase	Status	Title
NCT05819853	RESTORE	P3	recruiting	Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

Kidney Transplant Recipients (1)

NCT	Acronym	Phase	Status	Title
NCT05938712	HALLMARK	P2	recruiting	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Addiction (1)

NCT	Acronym	Phase	Status	Title
NCT06015893	STAR	P2	recruiting	Semaglutide Therapy for Alcohol Reduction (STAR)

Cystic Fibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT05788965	—	P2/P3	completed	Semaglutide in CFRD

Glucose Intolerance After a Recent History of Gestational Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT05569772	SERENA	P3	recruiting	Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Stroke (1)

NCT	Acronym	Phase	Status	Title
NCT05920889	GALLOP	P2	completed	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Fibrosis, Liver (1)

NCT	Acronym	Phase	Status	Title
NCT06005012	SAMARA	P2	unknown	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Metabolic Health (1)

NCT	Acronym	Phase	Status	Title
NCT06354101	—	N/A	withdrawn	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Non-alcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05877547	NASH	P2	completed	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Alzheimers Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05891496	—	P3	completed	A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

Pneumonia, Aspiration (1)

NCT	Acronym	Phase	Status	Title
NCT06154486	—	N/A	completed	Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

Alcohol Abuse (1)

NCT	Acronym	Phase	Status	Title
NCT05895643	SEMALCO	P2	completed	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

PCOS (Polycystic Ovary Syndrome) (1)

NCT	Acronym	Phase	Status	Title
NCT05702905	—	P4	unknown	Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Psoriasis Vulgaris (1)

NCT	Acronym	Phase	Status	Title
NCT06475586	—	P4	completed	Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Atherosclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT05870462	SEMA-VR	P4	unknown	Semaglutide and Vascular Regeneration

Aging (1)

NCT	Acronym	Phase	Status	Title
NCT05786521	—	P4	completed	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Klinefelter Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05586802	KLIN-HEALTH	P3	recruiting	Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Cardiovascular Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05669755	REDEFINE 3	P3	active not recruiting	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Metformin (1)

NCT	Acronym	Phase	Status	Title
NCT05779644	—	N/A	unknown	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Weight Change, Body (1)

NCT	Acronym	Phase	Status	Title
NCT05616052	—	P4	unknown	Comparison of Body Weight Change Through Different Smeglutide Administration Methods

Asthma (1)

NCT	Acronym	Phase	Status	Title
NCT05254314	GATA-3	P2	recruiting	Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

Tobacco Use Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT05530577	—	P2	completed	Effects of Semaglutide on Nicotine Intake

Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05371496	—	P2	enrolling by invitation	Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

Double Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT05305794	TOLEDDO	P3	recruiting	Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

Obesity, Adolescent (1)

NCT	Acronym	Phase	Status	Title
NCT05574439	RESETTLE	P4	completed	Young Adults With Early-onset Obesity Treated With Semaglutide

Schizophrenia Spectrum Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT05333003	Sema	N/A	active not recruiting	Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

Diabetes Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT06301191	—	N/A	unknown	The Effect of Semaglutide on Cardiovascular Markers and Liver Function

Healthy Volunteers (Diabetes Mellitus, Type 2) (1)

NCT	Acronym	Phase	Status	Title
NCT05232708	—	P1	completed	A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

Pre Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT04873050	SWEET	P4	recruiting	Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Pulmonary Embolism (1)

NCT	Acronym	Phase	Status	Title
NCT06118203	—	N/A	completed	Semaglutide Use in Acute Pulmonary Embolism

Schizophrenia (1)

NCT	Acronym	Phase	Status	Title
NCT05193578	HISTORI	P2	completed	Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Endothelial Dysfunction (1)

NCT	Acronym	Phase	Status	Title
NCT05857085	ENDIS	P4	completed	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Atheroscleroses, Coronary (1)

NCT	Acronym	Phase	Status	Title
NCT05071417	SEPLA	P3	unknown	Effect Of Semaglutide In Coronary Atheroma Plaque

Type 2 Diabetes Mellitus in Obese (1)

NCT	Acronym	Phase	Status	Title
NCT05606471	SemVLCD	P4	unknown	Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

Covid19 (1)

NCT	Acronym	Phase	Status	Title
NCT04615871	SEMPATICO	P2	unknown	Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

Metabolic Disturbance (1)

NCT	Acronym	Phase	Status	Title
NCT04892199	—	P4	active not recruiting	Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Nonalcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04944992	MK-6024	P2	completed	A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

CKD (1)

NCT	Acronym	Phase	Status	Title
NCT04741074	RAISE-KT	P3	terminated	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT04916470	STEP HFpEF DM	P3	completed	Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Early Alzheimer´s Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04777409	EVOKE Plus	P3	completed	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Early Alzheimer's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04777396	EVOKE	P3	completed	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

HIV Infections (1)

NCT	Acronym	Phase	Status	Title
NCT04216589	NAFLD	P2	completed	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Diabetes type2 (1)

NCT	Acronym	Phase	Status	Title
NCT04447859	—	P3	unknown	16-week Flexible vs. 8-week Semaglutide Titration

Type 2 Diabetes With Renal Manifestations (1)

NCT	Acronym	Phase	Status	Title
NCT04061200	EmpaSema	P4	unknown	Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Non-Alcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT03884075	NAFLD HEROES	P2	recruiting	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

HIV/AIDS (1)

NCT	Acronym	Phase	Status	Title
NCT04019197	—	P2	active not recruiting	Effects of Semaglutide in HIV-Associated Lipohypertrophy

Type 1 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03899402	—	P2/P3	active not recruiting	Triple Therapy in T1DM

Parkinson Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03659682	GIPD	P2	unknown	GLP1R in Parkinson's Disease

Metabolism and Nutrition Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT03574584	—	P1	completed	A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Non-diabetic Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06863363	—	P4	not yet recruiting	PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults

Semaglutide pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
ASCEND PLUS	NCT05441267	P4	recruiting	Diabetes Mellitus, Type 2	20,000	—
CASCADES	NCT07254572	P4	recruiting	Coronary Artery Disease	300	—
MOTIVATE	NCT07485062	P4	not yet recruiting	Type 2 Diabetes	164	—
SPICE-AF	NCT07389941	P4	not yet recruiting	Atrial Fibrillation (AF)	240	—
RAPID-CKD	NCT07547878	P4	not yet recruiting	Chronic Kidney Disease	64	—
OBOE-Mayo	NCT07213466	P4	recruiting	Bipolar I Disorder	100	—
ABSALON	NCT06792422	P4	recruiting	Primary Open Angle Glaucoma (POAG)	126	—
WAIT	NCT07275697	P4	not yet recruiting	Atrial Fibrillation (AF)	200	—
CKD-bioMatch	NCT07239570	P4	recruiting	Chronic Kidney Disease(CKD)	125	—
ONSET	NCT06986993	P4	recruiting	Tobacco Use	40	—
DECODE	NCT07483801	P4	not yet recruiting	Cardiovascular Diseases	112	—
JOULE-MARS	NCT06852391	P4	recruiting	Obesity (Disorder)	74	—
E-SEMPA	NCT06613854	P4	recruiting	Type 2 Diabetes Mellitus (T2DM)	90	—
Sema-RTx	NCT05702931	P4	recruiting	Hyperglycemia	104	—
STEP@STAH	NCT06754163	P4	active not recruiting	Obesity and Obesity-related Medical Conditions	20	—
SEMAMOOD	NCT07136714	P4	recruiting	Major Depressive Disorder	116	—
GUARD-1	NCT07017270	P4	not yet recruiting	Kidney Disease, Chronic	100	—
SEQ	NCT07242534	P4	recruiting	Infertility	62	PMID 37762856
SIGNAL	NCT06954090	P4	enrolling by invitation	Type 2 DM	50	—
GLUCOSE-MGH	NCT06003153	P4	recruiting	Genetic Predisposition	125	—
DUTCH-WAIST	NCT06184633	P4	recruiting	Atrial Fibrillation	280	—
STABLE-GLP1	NCT07314684	P4	recruiting	T2DM (Type 2 Diabetes Mellitus)	80	PMID 37622663
SEMAPSO	NCT07401992	P4	recruiting	Psoriasis (PsO)	62	—
SEABAR	NCT06287307	P4	not yet recruiting	Obesity	152	PMID 26641646
SemaFatCard	NCT06557811	P4	not yet recruiting	Diabetic Patients	88	PMID 28762019
GAINPCCONTROL	NCT06908694	P4	recruiting	Prostate Cancer	20	—
EPHIC-DIA2	NCT06851962	P4	active not recruiting	Diabetes Mellitus Type 2	504	—
RESETTLE	NCT05574439	P4	completed	Obesity, Adolescent	246	PMID 32921795
SWEET	NCT04873050	P4	recruiting	Pre Diabetes	102	—
COMBAT_T2_NASH	NCT04639414	P4	active not recruiting	Type 2 Diabetes	192	—
IIH:DUAL	NCT06027567	P4	completed	Idiopathic Intracranial Hypertension	38	—
MitoSema	NCT04854083	P4	unknown	Type2 Diabetes	50	—
REALYSE	NCT05035082	P4	completed	Diabetes Mellitus, Type 2	1,020	—
STABLE Wt Loss	NCT05548647	P4	completed	Obesity	120	PMID 38655793
SEMA	NCT05303857	P4	completed	Diabetes Mellitus, Type 2	107	—
SEMA-VR	NCT05870462	P4	unknown	Atherosclerosis	100	PMID 30847424
SIB	NCT04979130	P4	completed	Type 2 Diabetes	69	—
DOTAFLAME	NCT05597202	P4	unknown	Type 2 Diabetes	22	—
TRANSITION-T2D	NCT04538352	P4	completed	Type 2 Diabetes	60	PMID 39532398
SemVLCD	NCT05606471	P4	unknown	Type 2 Diabetes Mellitus in Obese	45	PMID 41850248
OSO	NCT05442450	P4	unknown	Obesity	116	PMID 41066034
ENDIS	NCT05857085	P4	completed	Endothelial Dysfunction	90	—
STOP	NCT03985384	P4	completed	Type 2 Diabetes	140	—
NOVO-GLP1	NCT04624672	P4	terminated	Diabetes Mellitus, Type 2	3	—
EmpaSema	NCT04061200	P4	unknown	Type 2 Diabetes With Renal Manifestations	80	PMID 38770818
PLASTIC	NCT07021937	P3	not yet recruiting	Obesity/Therapy	120	—
REIMAGINEYOUNG	NCT07282613	P3	not yet recruiting	Diabetes Mellitus, Type 2	80	—
SERENA	NCT05569772	P3	recruiting	Glucose Intolerance After a Recent History of Gestational Diabetes	252	—
Steno1	NCT06082063	P3	recruiting	Cardiovascular Diseases	2,000	PMID 39078403
REST	NCT07294950	P3	recruiting	Obesity (Disorder)	98	—
CRAVE	NCT07218354	P3	not yet recruiting	Alcohol Use Disorder	622	—
ESSENCE	NCT04822181	P3	active not recruiting	Non-alcoholic Steatohepatitis	1,205	PMID 39412509
AMAZE 8	NCT07400107	P3	not yet recruiting	Obesity	1,000	—
GLOW	NCT07428746	P3	not yet recruiting	Diabetes Mellitus, Type 2	20	—
TOLEDDO	NCT05305794	P3	recruiting	Double Diabetes	76	—
OBES1TY	NCT06909006	P3	not yet recruiting	Obesity in Diabetes	122	—
SEMINAL-AF	NCT06499857	P3	recruiting	Overweight or Obesity	200	—
RESTORE	NCT05819853	P3	recruiting	PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries	80	—
GALLOP2	NCT06788626	P3	not yet recruiting	Acute Ischemic Stroke	390	—
STARS	NCT07030621	P3	not yet recruiting	Acute Ischemic Stroke	436	PMID 35138767
T1-DISCO	NCT05819138	P3	recruiting	Diabetes Mellitus, Type 1	60	—
FOCUS	NCT03811561	P3	active not recruiting	Diabetes Mellitus, Type 2	1,500	—
REDEFINE 3	NCT05669755	P3	active not recruiting	Cardiovascular Disease	7,101	—
GLP1-SC	NCT07059377	P3	recruiting	Diabetes Mellitus, Type 2	100	—
KLIN-HEALTH	NCT05586802	P3	recruiting	Klinefelter Syndrome	150	—
EPIC-CT	NCT07297589	P3	recruiting	STEMI - ST Elevation Myocardial Infarction	136	—
SEMPA	NCT06894784	P3	recruiting	Diabetes Type 1	36	PMID 36942888
SEMPSO	NCT06937060	P3	recruiting	Psoriasis (PsO)	14	—
TRANSCEND-T2D-2	NCT06260722	P3	active not recruiting	Diabetes Mellitus, Type 2	1,250	—
Optimum 2	NCT06778967	P3	active not recruiting	Type 2 Diabetes Mellitus (T2DM)	1,100	—
STEP Young	NCT05726227	P3	active not recruiting	Obesity	210	—
REDEFINE 1	NCT05567796	P3	active not recruiting	Obesity	3,400	PMID 41328546
GALACTUS	NCT07295223	P3	recruiting	Acute Myocardial Infarction With ST Elevation	44	—
REIMAGINE 5	NCT06534411	P3	active not recruiting	Diabetes Mellitus, Type 2	1,023	—
PIONEER TEENS	NCT04596631	P3	completed	Diabetes Mellitus, Type 2	132	—
EVOKE Plus	NCT04777409	P3	completed	Early Alzheimer´s Disease	1,840	PMID 38901446
EVOKE	NCT04777396	P3	completed	Early Alzheimer's Disease	1,840	PMID 39780249
REIMAGINE 2	NCT06065540	P3	completed	Type 2 Diabetes Mellitus	2,734	—
SEPLA	NCT05071417	P3	unknown	Atheroscleroses, Coronary	120	—
REIMAGINE 1	NCT06323174	P3	completed	Type 2 Diabetes	189	—
REIMAGINE 3	NCT06323161	P3	completed	Type 2 Diabetes	274	—
BARI-STEP	NCT05073835	P3	active not recruiting	Obesity	70	—
PIONEER START	NCT05444153	P3	withdrawn	Diabetes Mellitus, Type 2	0	—
ACHIEVE-3	NCT06045221	P3	completed	Type 2 Diabetes	1,698	PMID 41765029
HD1916	NCT06161844	P3	completed	Type 2 Diabetes Mellitus	506	—
STEP12	NCT06041217	P3	completed	Overweight	242	—
SUSTAIN OPTIMIZE	NCT05514535	P3	completed	Diabetes Mellitus, Type 2	573	—
REDEFINE 6	NCT05996848	P3	completed	Obesity or Overweight	300	—
REDEFINE 2	NCT05394519	P3	completed	Overweight	1,200	PMID 40544432
OASIS 3	NCT05890976	P3	completed	Overweight	200	—
SOCRATES-AF	NCT04885634	P3	withdrawn	Atrial Fibrillation	0	—
STEP UP	NCT05646706	P3	completed	Obesity	1,407	PMID 40961952
REMODEL	NCT04865770	P3	completed	Diabetes Mellitus, Type 2	106	PMID 41207620
SURMOUNT-5	NCT05822830	P3	completed	Obesity	751	PMID 40980721
SOUL	NCT03914326	P3	completed	Diabetes Mellitus, Type 2	9,651	PMID 41627802
STRIDE	NCT04560998	P3	completed	Diabetes Mellitus, Type 2	792	PMID 40169145
LSS	NCT05087342	P3	completed	Obesity	119	—
SMART	NCT04889183	P3	completed	Obesity	125	PMID 39455729
OASIS 4	NCT05564117	P3	completed	Overweight	307	PMID 40934115
COMBINE 2	NCT05259033	P3	completed	Diabetes Mellitus, Type 2	683	PMID 39820580
FLOW	NCT03819153	P3	completed	Diabetes Mellitus, Type 2	3,533	PMID 41706532
STEP HFpEF DM	NCT04916470	P3	completed	Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2	617	PMID 39217564
OASIS 2	NCT05132088	P3	completed	Overweight and Obesity	201	PMID 40758358
STEP 10	NCT05040971	P3	completed	Obesity	207	PMID 39089293
SEMAT	NCT06489457	P3	completed	Type 2 Diabetes Mellitus	25	PMID 39511836
SELECT	NCT03574597	P3	completed	Overweight	17,604	PMID 33567185
OASIS 1	NCT05035095	P3	completed	Obesity	667	PMID 37385278
STEP-HFpEF	NCT04788511	P3	completed	Obesity	529	PMID 37622681
PIONEER PLUS	NCT04707469	P3	completed	Diabetes Mellitus, Type 2	1,606	PMID 37385279
RAISE-KT	NCT04741074	P3	terminated	CKD	15	—
STEP7	NCT04251156	P3	completed	Overweight	375	PMID 38330988
PIONEER 11	NCT04109547	P3	completed	Diabetes Mellitus, Type 2	521	PMID 38985162
PIONEER 12	NCT04017832	P3	completed	Diabetes Mellitus, Type 2	1,441	PMID 38985161
STEP 8	NCT04074161	P3	completed	Overweight	338	PMID 34775881
STEP 5	NCT03693430	P3	completed	Overweight	304	PMID 37605636
STEP 1	NCT03548935	P3	completed	Metabolism and Nutrition Disorder	1,961	PMID 35441470
SUSTAIN 11	NCT03689374	P3	completed	Diabetes Mellitus, Type 2	2,274	PMID 35546450
SURPASS-2	NCT03987919	P3	completed	Type 2 Diabetes	1,879	PMID 37000390
SUSTAIN SWITCH	NCT04287179	P3	withdrawn	Diabetes Mellitus, Type 2	0	—
STEP 6	NCT03811574	P3	completed	Overweight	401	PMID 33667417
SUSTAIN FORTE	NCT03989232	P3	completed	Diabetes Mellitus, Type 2	961	PMID 34293304
STEP 2	NCT03552757	P3	completed	Obesity	1,210	PMID 36801984
STEP 3	NCT03611582	P3	completed	Overweight	611	PMID 33625476
STEP 4	NCT03548987	P3	completed	Metabolism and Nutrition Disorder	902	PMID 33755728
SUSTAIN	NCT03061214	P3	completed	Diabetes	868	PMID 33074557
PIONEER 7	NCT02849080	P3	completed	Diabetes	504	PMID 31189520
SUSTAIN 8	NCT03136484	P3	completed	Diabetes	788	PMID 31897524
PIONEER 6	NCT02692716	P3	completed	Diabetes	3,183	PMID 35484580
PIONEER 8	NCT03021187	P3	completed	Diabetes	731	PMID 31530667
PIONEER 9	NCT03018028	P3	completed	Diabetes	243	PMID 32333875
SUSTAIN 10	NCT03191396	P3	completed	Diabetes	577	PMID 31539622
SUSTAIN 9	NCT03086330	P3	completed	Diabetes	302	PMID 30833170
PIONEER 10	NCT03015220	P3	completed	Diabetes	458	PMID 32333876
PIONEER 5	NCT02827708	P3	completed	Diabetes	324	PMID 31189517
PIONEER 4	NCT02863419	P3	completed	Diabetes	711	PMID 31186120
PIONEER 3	NCT02607865	P3	completed	Diabetes	1,864	PMID 30903796
PIONEER 2	NCT02863328	P3	completed	Diabetes	822	PMID 31530666
PIONEER 1	NCT02906930	P3	completed	Diabetes	703	PMID 35653556
SUSTAIN 7	NCT02648204	P3	completed	Diabetes	1,201	PMID 29557057
SUSTAIN™ 6	NCT01720446	P3	completed	Diabetes	3,297	PMID 29178519
SUSTAIN™	NCT02207374	P3	completed	Diabetes	601	PMID 29322610
SUSTAIN™ 5	NCT02305381	P3	completed	Diabetes	397	PMID 29688502
SUSTAIN™	NCT02254291	P3	completed	Diabetes	308	PMID 28786547
SUSTAIN™ 2	NCT01930188	P3	completed	Diabetes	1,231	PMID 29748996
SUSTAIN™ 4	NCT02128932	P3	completed	Diabetes	1,089	PMID 28344112
SUSTAIN™ 3	NCT01885208	P3	completed	Diabetes	813	PMID 30047216
SUSTAIN™1	NCT02054897	P3	completed	Diabetes	388	PMID 29687620
STAR	NCT06015893	P2	recruiting	Addiction	80	PMID 26080318
GEM	NCT07204249	P2	recruiting	Methamphetamine-dependence	162	—
GL1DER HIV RCT	NCT07221214	P2	recruiting	HIV	200	—
REINFORCE	NCT07325500	P2	recruiting	Weight Gain	30	—
LEAST	NCT07511543	P2	not yet recruiting	Ischemic Stroke	100	—
HASHTAG	NCT07523633	P2	recruiting	Cannabis Use Disorder	100	—
HALLMARK	NCT05938712	P2	recruiting	Kidney Transplant Recipients	20	—
PLATEAU	NCT07446998	P2	recruiting	Obesity & Overweight	200	—
RT1D	NCT05822609	P2	recruiting	Diabetic Kidney Disease	60	PMID 40693871
ASSET	NCT05630586	P2	recruiting	Acute Ischemic Stroke	380	—
OBA	NCT07411378	P2	not yet recruiting	Muscle Wasting	164	—
SLIMMER-UP-SWITCH	NCT07073417	P2	active not recruiting	Obesity	163	—
HARP	NCT07040592	P2	recruiting	Alcohol Use Disorder (AUD)	30	—
QUEST	NCT04873245	P2	active not recruiting	Obesity, Childhood	120	—
SHIFT	NCT07509112	P2	not yet recruiting	Methamphetamine Use Disorder	40	—
STAC	NCT06691243	P2	recruiting	Cocaine Use Disorder	40	—
PROACT	NCT07101939	P2	recruiting	Obesity	120	—
SLIMM	NCT05173714	P2	recruiting	Chronic Kidney Diseases	156	—
CBeyond	NCT06577090	P2	active not recruiting	Obesity	136	—
PROTECT	NCT06449625	P2	not yet recruiting	Intestinal Mucositis	40	PMID 39384243
GATA-3	NCT05254314	P2	recruiting	Asthma	100	PMID 41567689
COURAGE	NCT06299098	P2	active not recruiting	Obesity	1,005	—
NAFLD HEROES	NCT03884075	P2	recruiting	Non-Alcoholic Steatohepatitis	84	—
SHORE	NCT06639464	P2	recruiting	Opioid Use Disorder	46	—
T2DM	NCT07163624	P2	completed	Type 2 Diabetes Mellitus (T2DM)	211	—
NASH	NCT05877547	P2	completed	Non-alcoholic Fatty Liver Disease	381	—
SOLSTICE	NCT06579105	P2	completed	Diabetes Mellitus, Type 2	406	—
AUD	NCT05892432	P2	completed	Alcohol Use Disorder	50	—
STAR-T	NCT05891587	P2	completed	Alcohol Use Disorder	80	—
QUALITY	NCT06282458	P2	completed	Muscle Loss	168	—
SEMALCO	NCT05895643	P2	completed	Alcohol Abuse	108	PMID 39779270
SAMARA	NCT06005012	P2	unknown	Fibrosis, Liver	120	—
NASH	NCT05016882	P2	completed	Non-alcoholic Steatohepatitis	698	—
GIPD	NCT03659682	P2	unknown	Parkinson Disease	120	—
WAYFIND	NCT04971785	P2	completed	Nonalcoholic Steatohepatitis	457	—
GALLOP	NCT05920889	P2	completed	Stroke	140	PMID 41392086
WP3	NCT05897372	P2	terminated	Diabetic Kidney Disease	1	—
GLP-1	NCT06500429	P2	completed	Overweight and Obesity	120	—
ADJUST-T1D	NCT05537233	P2	completed	Type 1 Diabetes	115	PMID 40550013
HISTORI	NCT05193578	P2	completed	Schizophrenia	154	PMID 38503415
NAFLD	NCT04216589	P2	completed	HIV Infections	51	PMID 41299212
MK-6024	NCT04944992	P2	completed	Nonalcoholic Fatty Liver Disease	145	PMID 37355043
SEMPATICO	NCT04615871	P2	unknown	Covid19	400	—
NASH	NCT03987074	P2	completed	Nonalcoholic Steatohepatitis	109	—

Terminated and withdrawn Semaglutide trials (19)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05829460withdrawnPrimary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
NCT05209165suspendedSemaglutide to Reduce Atrial Fibrillation Burden
NCT06083675withdrawnResearch Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
NCT06222437withdrawnSemaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
NCT07172867withdrawnA Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
NCT07081178terminatedA Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
NCT05444153withdrawnResearch Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
NCT06619015withdrawnTailoring Obesity Treatment Trial
NCT06468748withdrawnThe Effects of Semaglutide on Body Composition and Performance in Military Personnel
NCT04885634withdrawnSemaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
NCT05897372terminatedFeasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05473286withdrawnA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
NCT05671653terminatedA Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
NCT06354101withdrawnThe Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.
NCT04938388terminatedComparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
NCT04741074terminatedEffect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
NCT04624672terminatedTreatment of GLP-1 for Diabetic Bariatric Patients
NCT04287179withdrawnSUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT04012255terminatedA Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

All Semaglutide trials (537)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT05441267	ASCEND PLUS	A Study of Cardiovascular Events iN Diabetes Plus	P4	recruiting	20,000	University of Oxford	Mar 2023
NCT06934655		Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth	P3	not yet recruiting	150	Children's Hospital Los Angeles	Jun 2026
NCT07253285		A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	P3	recruiting	460	Novo Nordisk A/S	Jan 2026
NCT05501483	DiaSpax	Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes	N/A	recruiting	60	Karolinska Institutet	Feb 2023
NCT05829460		Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia	P2	withdrawn	0	Washington University School of Medicine	Mar 2025
NCT06977438		Promoting Healthy Children and Youth	P4	not yet recruiting	1,020	University of Minnesota	Jan 2027
NCT06571383		STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss	P4	active not recruiting	500	Novo Nordisk A/S	Sep 2024
NCT07135245		Improved Treatment and Monitoring of Alzheimer's Disease	P2	not yet recruiting	180	Rune Skovgaard Rasmussen	Jan 2026
NCT07021937	PLASTIC	Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity	P3	not yet recruiting	120	University of Colorado, Denver	May 2026
NCT06015893	STAR	Semaglutide Therapy for Alcohol Reduction (STAR)	P2	recruiting	80	National Institute on Drug Abuse (NIDA)	Oct 2023
NCT06975111		Focusing on the Menopausal Transition to Improve Mid-Life Women's Health	P2/P3	recruiting	200	University of Colorado, Denver	Mar 2026
NCT07361874	IMPACT-MACS	IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion	N/A	recruiting	75	University of Texas Southwestern Medical Center	Mar 2026
NCT07282613	REIMAGINEYOUNG	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes	P3	not yet recruiting	80	Novo Nordisk A/S	Aug 2026
NCT07204249	GEM	Glutide for Ending Methamphetamine	P2	recruiting	162	San Francisco Department of Public Health	Feb 2026
NCT07221214	GL1DER HIV RCT	GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	P2	recruiting	200	Vanderbilt University Medical Center	Apr 2026
NCT07430332		GLP-1 RA for Stage 1 Type 1 Diabetes	P2	not yet recruiting	15	Children's Hospital Medical Center, Cincinnati	Sep 2027
NCT05569772	SERENA	Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes	P3	recruiting	252	Universitaire Ziekenhuizen KU Leuven	Sep 2023
NCT07091500	GLP-1	Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity	N/A	recruiting	40	Washington University School of Medicine	Aug 2025
NCT07254572	CASCADES	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	P4	recruiting	300	National Institute of Cardiology, Warsaw, Poland	Jul 2025
NCT06082063	Steno1	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes	P3	recruiting	2,000	Steno Diabetes Center Copenhagen	Jul 2024
NCT07325500	REINFORCE	Incretin Microdosing for Cardiometabolic Health in People With HIV	P2	recruiting	30	The University of Texas Health Science Center, Houston	Feb 2026
NCT07294950	REST	Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination	P3	recruiting	98	Mount Sinai Hospital, Canada	Feb 2026
NCT07218354	CRAVE	Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder	P3	not yet recruiting	622	VA Office of Research and Development	Jul 2026
NCT07485062	MOTIVATE	Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes	P4	not yet recruiting	164	Western University, Canada	May 2026
NCT07389941	SPICE-AF	Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation	P4	not yet recruiting	240	University of Luebeck	Oct 2026
NCT04822181	ESSENCE	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	P3	active not recruiting	1,205	Novo Nordisk A/S	Apr 2021
NCT07547878	RAPID-CKD	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)	P4	not yet recruiting	64	Baylor Research Institute	Apr 2026
NCT06706284		Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	P4	recruiting	50	Marzieh Salehi	Apr 2025
NCT07227948		Repurposing Semaglutide for the Treatment of Cocaine Use Disorder	P2	recruiting	75	The University of Texas Health Science Center, Houston	Jan 2026
NCT07213466	OBOE-Mayo	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder	P4	recruiting	100	Mayo Clinic	Jan 2026
NCT07400107	AMAZE 8	AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	P3	not yet recruiting	1,000	Novo Nordisk A/S	May 2026
NCT07391267	MAFLD	Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.	N/A	not yet recruiting	90	Institute of Liver and Biliary Sciences, India	Feb 2026
NCT07302802		Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice	—	recruiting	70	Prof. Dr. Martin Wabitsch	Dec 2025
NCT07200622		Oral Semaglutide in Patients With Alzheimer's Disease	P2	not yet recruiting	60	Imperial College London	Sep 2025
NCT06792422	ABSALON	A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma	P4	recruiting	126	Glostrup University Hospital, Copenhagen	Jan 2025
NCT07275697	WAIT	Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study	P4	not yet recruiting	200	Emma Svennberg	Dec 2025
NCT06072963		COMMETS- Combination MCI Metabolic Syndrome	P2	recruiting	80	Rutgers, The State University of New Jersey	Jan 2024
NCT07428746	GLOW	Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes	P3	not yet recruiting	20	Emory University	Apr 2026
NCT06814938		A Study of a Novel Precision Medicine Approach For Obesity	P4	active not recruiting	135	Mayo Clinic	Feb 2025
NCT06762314		Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	P2	recruiting	105	Mostafa Bahaa	Jan 2025
NCT06780449		A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity	P3	active not recruiting	400	Novo Nordisk A/S	Feb 2025
NCT07011667		A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term	P3	active not recruiting	609	Novo Nordisk A/S	Jun 2025
NCT06042153		DIALYSIS-TIR Study	P4	active not recruiting	43	University of Texas Southwestern Medical Center	Dec 2023
NCT05305794	TOLEDDO	Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"	P3	recruiting	76	Centre Hospitalier Universitaire Dijon	Jul 2022
NCT07055607	PILLAR	A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice	—	enrolling by invitation	1,250	Novo Nordisk A/S	May 2025
NCT07073053		The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms	P4	not yet recruiting	60	Taipei Veterans General Hospital, Taiwan	Oct 2025
NCT07065383	Re-CHARM	Rebalancing the Fat Content of the Heart and Muscles	N/A	recruiting	60	University of Aberdeen	Aug 2025
NCT07511543	LEAST	Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy	P2	not yet recruiting	100	Population Health Research Institute	Jun 2026
NCT07317115	MAGvMED	Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes	N/A	recruiting	20	GT Metabolic Solutions, Inc.	Mar 2026
NCT06909006	OBES1TY	Semaglutide Treatment in Type 1 Diabetes	P3	not yet recruiting	122	Nordsjaellands Hospital	Oct 2025
NCT07239570	CKD-bioMatch	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	P4	recruiting	125	Peter Rossing	Jun 2025
NCT06499857	SEMINAL-AF	Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation	P3	recruiting	200	University of Chicago	Apr 2025
NCT06411210		Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment	P2	recruiting	54	Yale University	Jul 2024
NCT06986993	ONSET	Impact of Semaglutide on Tobacco Use and Related Health Behaviors	P4	recruiting	40	University of Oklahoma	Jul 2024
NCT05819853	RESTORE	Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome	P3	recruiting	80	University of Colorado, Denver	Nov 2023
NCT07527195	RASMUS	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)	P1	recruiting	100	Novo Nordisk A/S	Apr 2026
NCT05209165		Semaglutide to Reduce Atrial Fibrillation Burden	P4	suspended	132	San Francisco Veterans Affairs Medical Center	May 2023
NCT07010432	RAMBO	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism	P1	recruiting	144	Novo Nordisk A/S	Jun 2025
NCT07523633	HASHTAG	Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	P2	recruiting	100	Anders Fink-Jensen, MD, DMSci	Apr 2026
NCT07483801	DECODE	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	P4	not yet recruiting	112	Cambridge University Hospitals NHS Foundation Trust	Mar 2026
NCT07564414		A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	P3	recruiting	2,500	Novo Nordisk A/S	May 2026
NCT07284979		Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	P3	recruiting	1,200	Kailera	Dec 2025
NCT07202247		Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	P2	recruiting	60	City of Hope Medical Center	Jan 2026
NCT06801015		Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions	P4	active not recruiting	30	Mayo Clinic	Oct 2025
NCT05938712	HALLMARK	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients	P2	recruiting	20	University Health Network, Toronto	Oct 2023
NCT06788626	GALLOP2	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment	P3	not yet recruiting	390	Wei Hu	Feb 2025
NCT07030621	STARS	Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial	P3	not yet recruiting	436	RenJi Hospital	Jul 2025
NCT06283667		Special Use - Results Surveillance on Long-term Use With Wegovy®	—	active not recruiting	1,071	Novo Nordisk A/S	Jun 2024
NCT07446998	PLATEAU	Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	P2	recruiting	200	Veru Inc.	Mar 2026
NCT06852391	JOULE-MARS	JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity	P4	recruiting	74	McMaster University	Jun 2025
NCT06825793		Semaglutide's Weight Loss Effects in Obesity	N/A	not yet recruiting	56	Beijing Chao Yang Hospital	Feb 2025
NCT06613854	E-SEMPA	Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes	P4	recruiting	90	University Medical Centre Ljubljana	Oct 2024
NCT05702931	Sema-RTx	Semaglutide Treatment for Hyperglycaemia After Renal Transplantation	P4	recruiting	104	Rigshospitalet, Denmark	Sep 2024
NCT06461377		The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy	P4	recruiting	50	The First Affiliated Hospital with Nanjing Medical University	Jun 2024
NCT05822609	RT1D	Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes	P2	recruiting	60	University of Washington	Apr 2024
NCT05630586	ASSET	Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke	P2	recruiting	380	Aarhus University Hospital	Apr 2023
NCT05071898	PORT	Pharmacogenetics of Response to GLP1R Agonists	P1	recruiting	600	University of Maryland, Baltimore	Apr 2022
NCT06754163	STEP@STAH	Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients	P4	active not recruiting	20	St Andrew's Healthcare	Jan 2025
NCT05746039		Feasibility of Semaglutide in Advanced Lung Disease	P1/P2	recruiting	8	University of Pennsylvania	Jan 2024
NCT06803888		Bariatric Surgery vs. Semaglutide vs. Tirzepatide	P4	active not recruiting	125	Ali Aminian	Jan 2025
NCT05819138	T1-DISCO	Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes	P3	recruiting	60	University of Colorado, Denver	Jun 2023
NCT06913023	SPOT-DM	Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus	P2/P3	not yet recruiting	74	University Health Network, Toronto	Jan 2026
NCT03811561	FOCUS	A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes	P3	active not recruiting	1,500	Novo Nordisk A/S	May 2019
NCT07280221		WEgovy Real World Assessment of Weight Loss in Korea	—	enrolling by invitation	500	Novo Nordisk A/S	Nov 2025
NCT05669755	REDEFINE 3	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels	P3	active not recruiting	7,101	Novo Nordisk A/S	Mar 2023
NCT07184086		A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet	P1	recruiting	80	Novo Nordisk A/S	Sep 2025
NCT07415954		A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes	P2	recruiting	270	Novo Nordisk A/S	Apr 2026
NCT06575738	PRESSURE	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	P1	recruiting	40	University of Colorado, Denver	Oct 2024
NCT07136714	SEMAMOOD	Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity	P4	recruiting	116	Nordsjaellands Hospital	Sep 2025
NCT07017270	GUARD-1	Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis	P4	not yet recruiting	100	Unity Health Toronto	Jul 2025
NCT07411378	OBA	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.	P2	not yet recruiting	164	Biophytis	Jul 2026
NCT07073417	SLIMMER-UP-SWITCH	A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)	P2	active not recruiting	163	Hangzhou Sciwind Biosciences Co., Ltd.	Jul 2025
NCT07059377	GLP1-SC	Semaglutide for Smoking Cessation in Patients With Diabetes	P3	recruiting	100	Ottawa Heart Institute Research Corporation	Feb 2026
NCT04174755	SWIFT	Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV	N/A	recruiting	80	University College Dublin	Jun 2022
NCT07466017		A Study of CS060380 Tablets in Patients With MASH and Obesity	P2	recruiting	120	Cascade Pharmaceuticals, Inc	Apr 2026
NCT07040592	HARP	Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide	P2	recruiting	30	Yale University	Jan 2026
NCT07150975		Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects	P3	recruiting	420	Gan & Lee Pharmaceuticals.	Sep 2025
NCT06884293		A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）	P3	active not recruiting	479	Innovent Biologics (Suzhou) Co. Ltd.	May 2025
NCT04873245	QUEST	Lifestyle Counseling and Medication for Adolescent Weight Management	P2	active not recruiting	120	University of Minnesota	Mar 2022
NCT07293325		Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	N/A	recruiting	66	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jun 2025
NCT06318442		The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes	N/A	recruiting	60	Imperial College London	May 2024
NCT05689372		Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	—	enrolling by invitation	600	Novo Nordisk A/S	Feb 2026
NCT07242534	SEQ	Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.	P4	recruiting	62	Fundacion Dexeus	Jan 2026
NCT06954090	SIGNAL	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	P4	enrolling by invitation	50	Steno Diabetes Center Copenhagen	Nov 2025
NCT06003153	GLUCOSE-MGH	GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH	P4	recruiting	125	Massachusetts General Hospital	Mar 2024
NCT06083675		Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes	P3	withdrawn	0	Novo Nordisk A/S	Jan 2024
NCT06836284		The Evira Study: Additional Support During Obesity Treatment	N/A	recruiting	40	Karolinska Institutet	Feb 2026
NCT06184633	DUTCH-WAIST	DUTCH Weight Control in Atrial Fibrillation Study	P4	recruiting	280	Rijnstate Hospital	Jul 2024
NCT06546384	GLP-1 RA	GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease	N/A	not yet recruiting	64	Insel Gruppe AG, University Hospital Bern	May 2026
NCT05586802	KLIN-HEALTH	Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome	P3	recruiting	150	Georgios Papadakis	Mar 2023
NCT07509112	SHIFT	Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study	P2	not yet recruiting	40	Kirby Institute	May 2026
NCT07297589	EPIC-CT	Epicardial Cardiac Fat-CT (EPIC-CT)	P3	recruiting	136	Instituto Mexicano del Seguro Social	Dec 2025
NCT07285902		A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity	P3	active not recruiting	572	Fujian Shengdi Pharmaceutical Co., Ltd.	Dec 2025
NCT06691243	STAC	Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV	P2	recruiting	40	University of Maryland, Baltimore	Aug 2025
NCT07101939	PROACT	A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)	P2	recruiting	120	Actimed Therapeutics Ltd	Jun 2025
NCT07057310		Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	P4	enrolling by invitation	30	Mayo Clinic	May 2025
NCT06338553	GLP-TEP	GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab	Early P1	recruiting	24	Vanderbilt University Medical Center	Jun 2024
NCT05173714	SLIMM	Sit Less, Interact and Move More (SLIMM) 2 Study	P2	recruiting	156	Srinvasan Beddhu	Dec 2021
NCT07314684	STABLE-GLP1	GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM	P4	recruiting	80	Federico II University	Sep 2025
NCT07282769		Semaglutide (Wegovy) Treatment for Trichotillomania	P2	not yet recruiting	10	University of Chicago	Jun 2026
NCT06222437		Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy	P1	withdrawn	0	Methodist Health System	Feb 2026
NCT07401992	SEMAPSO	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis	P4	recruiting	62	Hospital Universitario Dr. Jose E. Gonzalez	Jan 2026
NCT06577090	CBeyond	Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo	P2	active not recruiting	136	Skye Bioscience, Inc.	Aug 2024
NCT06449625	PROTECT	Semaglutide in Auto-HSCT	P2	not yet recruiting	40	Klaus Gottlob Müller	Aug 2024
NCT06894784	SEMPA	A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes	P3	recruiting	36	McGill University Health Centre/Research Institute of the McGill University Health Centre	Apr 2025
NCT06937060	SEMPSO	Effect of Semaglutide in Patients With Psoriasis and Obesity	P3	recruiting	14	The University of Hong Kong	Mar 2025
NCT06387199	SEMA SMA	Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide	P2/P3	recruiting	26	McGill University Health Centre/Research Institute of the McGill University Health Centre	Dec 2024
NCT06260722	TRANSCEND-T2D-2	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	P3	active not recruiting	1,250	Eli Lilly and Company	Feb 2024
NCT05067621		Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	P2	active not recruiting	60	Yale University	Jul 2023
NCT07457424	DIGRAT	Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)	—	active not recruiting	140	University College Dublin	Feb 2022
NCT06050577		The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial	P2	active not recruiting	64	Odense University Hospital	Jun 2024
NCT06745284		A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity	P1	active not recruiting	64	Boehringer Ingelheim	Mar 2025
NCT07179120		Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	P2	not yet recruiting	180	First Affiliated Hospital of Wenzhou Medical University	May 2026
NCT07251556		GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis	P4	not yet recruiting	40	Chinese University of Hong Kong	Dec 2025
NCT05202353		A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver	P1	recruiting	30	Boehringer Ingelheim	Oct 2024
NCT07570810		Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM	N/A	not yet recruiting	30	Shanghai Jiao Tong University School of Medicine	Jun 2026
NCT07187856		Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus	P2	not yet recruiting	80	ProGen. Co., Ltd.	Jan 2026
NCT07319975		Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	N/A	not yet recruiting	48	Istanbul Galata University	Dec 2025
NCT07165158		The Effect of Semaglutide on Bone Health	P4	not yet recruiting	150	The First Affiliated Hospital of Xiamen University	Sep 2025
NCT07139548		A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes	P3	not yet recruiting	600	Guangdong Raynovent Biotech Co., Ltd	Aug 2025
NCT06989203		Protein Supplementation Intervention on Body Weight	N/A	recruiting	140	Chinese Academy of Sciences	Jun 2025
NCT06989177		Probiotic Intervention on Body Weight	N/A	recruiting	140	Chinese Academy of Sciences	Jun 2025
NCT05780905		Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes	P4	recruiting	50	University of Washington	Jan 2024
NCT06959784		Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)	P4	enrolling by invitation	142	China-Japan Friendship Hospital	Jan 2024
NCT05195944		Semaglutide vs Sitagliptin	P4	enrolling by invitation	58	University Health Network, Toronto	Oct 2022
NCT05254314	GATA-3	Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)	P2	recruiting	100	Vanderbilt University Medical Center	Oct 2022
NCT04451837		Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology	P2	active not recruiting	200	Region Skane	Sep 2020
NCT06423599	FIT-HF	Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure	P2/P3	recruiting	100	Jens D Hove, MD,PHD	May 2024
NCT06778967	Optimum 2	A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus	P3	active not recruiting	1,100	Gan & Lee Pharmaceuticals.	Feb 2025
NCT05726227	STEP Young	A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight	P3	active not recruiting	210	Novo Nordisk A/S	Jul 2023
NCT07513168		Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults	P4	recruiting	60	Asian Institute Of Medical Sciences	Aug 2025
NCT06982859		A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	P1	recruiting	95	Eli Lilly and Company	Jun 2025
NCT06548490		GLP-1R Agonist Treatment for Opioid Use Disorder	P2	recruiting	200	Milton S. Hershey Medical Center	Jan 2025
NCT06234111		Semaglutide and Physical Activity for Obesity and Multimorbidity	—	active not recruiting	35	Hvidovre University Hospital	Feb 2024
NCT07112872		A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes	P2	active not recruiting	240	Hoffmann-La Roche	Aug 2025
NCT07505303		MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial	P2	not yet recruiting	160	Eccogene	Mar 2026
NCT06716216		A Study of BGM0504 in Participants with Type 2 Diabetes	P3	recruiting	537	BrightGene Bio-Medical Technology Co., Ltd.	Nov 2024
NCT07223983	SEMA	Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	P1	recruiting	10	Yale University	Mar 2026
NCT06616961		Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus	P3	not yet recruiting	480	Popular Medical College Hospital	Nov 2024
NCT05119179		Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes	P4	recruiting	300	The University of Texas Health Science Center, Houston	Nov 2021
NCT05714683		Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea	—	not yet recruiting	600	Novo Nordisk A/S	Dec 2025
NCT06633783		A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®	P3	not yet recruiting	370	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,	Oct 2024
NCT06299098	COURAGE	A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation	P2	active not recruiting	1,005	Regeneron Pharmaceuticals	Mar 2024
NCT05567796	REDEFINE 1	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	P3	active not recruiting	3,400	Novo Nordisk A/S	Nov 2022
NCT03884075	NAFLD HEROES	Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)	P2	recruiting	84	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Jul 2019
NCT06980623		Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	—	active not recruiting	26,000	Brigham and Women's Hospital	Jan 2025
NCT07430059	SLIM-1	Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant	P1	not yet recruiting	20	Vivani Medical, Inc	Apr 2026
NCT07195994		A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes	N/A	recruiting	90	QuickSilver Scientific	Feb 2026
NCT07295223	GALACTUS	Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)	P3	recruiting	44	Instituto Mexicano del Seguro Social	Dec 2025
NCT06649344		A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes	P3	active not recruiting	884	Fujian Shengdi Pharmaceutical Co., Ltd.	Oct 2024
NCT06287307	SEABAR	Semaglutide 2.4mg for Low Responders After Bariatric Surgery	P4	not yet recruiting	152	Zuyderland Medisch Centrum	May 2024
NCT07087795		A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes	P1	active not recruiting	96	Novo Nordisk A/S	Jul 2025
NCT06717698		A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease	P2	recruiting	465	Novo Nordisk A/S	Dec 2024
NCT06557811	SemaFatCard	Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction	P4	not yet recruiting	88	University of Sao Paulo General Hospital	Sep 2024
NCT04019197		Effects of Semaglutide in HIV-Associated Lipohypertrophy	P2	active not recruiting	108	Case Western Reserve University	May 2019
NCT06639464	SHORE	Semaglutide for Helping Opioid Recovery	P2	recruiting	46	Brigham and Women's Hospital	Jun 2025
NCT07374328	TRED	Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus	P1/P2	recruiting	240	Second Affiliated Hospital of Guangzhou Medical University	Jun 2025
NCT06738979		A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects	P3	not yet recruiting	408	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Mar 2025
NCT06827002		Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults	P1/P2	active not recruiting	248	University of Yaounde 1	Mar 2023
NCT05371496		Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	P2	enrolling by invitation	81	Mayo Clinic	Sep 2022
NCT05333003	Sema	Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity	N/A	active not recruiting	92	Centre for Addiction and Mental Health	May 2022
NCT07465965		A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults	P1	recruiting	60	Shanghai World Leader Pharmaceutical Co., Ltd.	Mar 2026
NCT06797869		A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy	P2	active not recruiting	142	Novo Nordisk A/S	Jan 2025
NCT07554417		Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1	P4	not yet recruiting	20	William Marsh Rice University	Apr 2026
NCT07271251		A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes	P3	active not recruiting	264	Novo Nordisk A/S	Dec 2025
NCT07323134		The Effect of Semaglutide on the Intestinal Flora in Obesity	—	not yet recruiting	40	Beijing Chao Yang Hospital	Feb 2026
NCT06173778		Semaglutide for Post-Smoking Cessation Weight Management	P2	recruiting	197	The University of Texas Health Science Center, Houston	Apr 2024
NCT05424003		Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	P2	recruiting	50	University of Virginia	Feb 2024
NCT04892199		Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	P4	active not recruiting	104	Anders Fink-Jensen, MD, DMSci	Sep 2021
NCT07064486		A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia	P3	recruiting	477	BrightGene Bio-Medical Technology Co., Ltd.	Jul 2025
NCT06908694	GAINPCCONTROL	Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy	P4	recruiting	20	Hamilton Health Sciences Corporation	Jul 2025
NCT06410352		Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome	P4	recruiting	220	University Medical Center, Kazakhstan	Mar 2024
NCT05984238	EMINENT-2	A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)	N/A	active not recruiting	32	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Aug 2023
NCT07225816		Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	P1	recruiting	75	Novo Nordisk A/S	Nov 2025
NCT06534411	REIMAGINE 5	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	P3	active not recruiting	1,023	Novo Nordisk A/S	Nov 2024
NCT07272343		The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes	P4	recruiting	100	Second Affiliated Hospital of Nanchang University	Feb 2023
NCT06851962	EPHIC-DIA2	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.	P4	active not recruiting	504	Fundación para la Investigación del Hospital Clínico de Valencia	May 2025
NCT03899402		Triple Therapy in T1DM	P2/P3	active not recruiting	78	State University of New York at Buffalo	May 2019
NCT07424430	SEMA-CKM	Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes	—	not yet recruiting	400	LMC Diabetes & Endocrinology Ltd.	Mar 2026
NCT06764056	METAfoie	Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)	N/A	not yet recruiting	120	Institut universitaire de cardiologie et de pneumologie de Québec, University Laval	Jan 2025
NCT07390110		Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)	—	active not recruiting	25,664	Brigham and Women's Hospital	Jan 2026
NCT07417618	INTERCEPT	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	—	active not recruiting	60,000	Brigham and Women's Hospital	Jan 2026
NCT06388187		A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight	P3	completed	300	Novo Nordisk A/S	Jun 2024
NCT06221969		A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	P3	completed	1,024	Novo Nordisk A/S	Jan 2024
NCT05574439	RESETTLE	Young Adults With Early-onset Obesity Treated With Semaglutide	P4	completed	246	Signe Torekov	Jun 2022
NCT06269120		SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary	—	recruiting	470	Novo Nordisk A/S	Sep 2024
NCT06779929	SURPASS CVOT	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	—	completed	70,000	Brigham and Women's Hospital	Nov 2024
NCT04873050	SWEET	Treatment to Regress to Normoglycemia in Women with a Recent History of GDM	P4	recruiting	102	Woman's	Jan 2022
NCT06396416		Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2	P4	recruiting	60	Western University, Canada	Sep 2024
NCT05756764		Anti-obesity Pharmacotherapy and Inflammation	—	active not recruiting	30	Louisiana State University Health Sciences Center in New Orleans	Jun 2023
NCT06184568		A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity	P3	completed	349	Innovent Biologics (Suzhou) Co. Ltd.	Feb 2024
NCT04596631	PIONEER TEENS	A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	P3	completed	132	Novo Nordisk A/S	Nov 2020
NCT06403761		Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes	P1	completed	158	Novo Nordisk A/S	May 2024
NCT05419726		Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.	—	recruiting	20	University of California, Los Angeles	Feb 2023
NCT07281196		Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea	—	completed	15	Shanghai Fengxian District Central Hospital	Jan 2025
NCT04777409	EVOKE Plus	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)	P3	completed	1,840	Novo Nordisk A/S	May 2021
NCT04777396	EVOKE	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)	P3	completed	1,840	Novo Nordisk A/S	May 2021
NCT07172867		A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM	P2	withdrawn	0	Halia Therapeutics, Inc.	Jan 2026
NCT06409130		Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease	P2	completed	270	Novo Nordisk A/S	May 2024
NCT06131437		A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	P3	completed	809	Novo Nordisk A/S	Nov 2023
NCT06065540	REIMAGINE 2	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	P3	completed	2,734	Novo Nordisk A/S	Sep 2023
NCT06896981		Semaglutide in Women With Polycystic Ovary Syndrome and Obesity	P2/P3	recruiting	30	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Feb 2025
NCT05340868	GAROS	Genetics of the Acute Response to Oral Semaglutide	N/A	recruiting	1,000	Medical University of Bialystok	Sep 2022
NCT05071417	SEPLA	Effect Of Semaglutide In Coronary Atheroma Plaque	P3	unknown	120	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León	Nov 2021
NCT04639414	COMBAT_T2_NASH	Combined Active Treatment in Type 2 Diabetes with NASH	P4	active not recruiting	192	German Diabetes Center	Mar 2021
NCT07163624	T2DM	UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study	P2	completed	211	The United Bio-Technology (Hengqin) Co., Ltd.	Mar 2025
NCT05646199	PCOS	Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)	P2/P3	unknown	60	University of Hull	Mar 2025
NCT06339086		Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes	P3	unknown	478	Chengdu Brilliant Pharmaceutical Co., Ltd.	Apr 2024
NCT05877547	NASH	A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	P2	completed	381	Merck Sharp & Dohme LLC	Jun 2023
NCT06323174	REIMAGINE 1	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise	P3	completed	189	Novo Nordisk A/S	Mar 2024
NCT06579105	SOLSTICE	Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.	P2	completed	406	AstraZeneca	Oct 2024
NCT07081178	WeGoReal	A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).	—	terminated	100	Novo Nordisk A/S	Aug 2025
NCT06267092		A Study of How CagriSema Works on Appetite in People With Excess Body Weight	P1	completed	164	Novo Nordisk A/S	Feb 2024
NCT06608433	PIANO	Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function	N/A	completed	22	University Hospital, Basel, Switzerland	Jan 2025
NCT05892432	AUD	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)	P2	completed	50	University of Colorado, Denver	Jan 2024
NCT06131372		A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	P2	completed	626	Novo Nordisk A/S	Apr 2024
NCT06060392	Sema-Lit	Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus	N/A	recruiting	50	Medanta, The Medicity, India	Oct 2023
NCT06027567	IIH:DUAL	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure	P4	completed	38	Rigmor Højland Jensen	Sep 2022
NCT06323161	REIMAGINE 3	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	P3	completed	274	Novo Nordisk A/S	Mar 2024
NCT05891587	STAR-T	Semaglutide Therapy for Alcohol Reduction - Tulsa	P2	completed	80	Oklahoma State University Center for Health Sciences	Jul 2023
NCT05073835	BARI-STEP	Semaglutide 2.4 mg in Patients With Poor Weight-loss	P3	active not recruiting	70	University College, London	Nov 2022
NCT06604624		Semaglutide in Treatment of Obesity	P3	completed	462	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Sep 2024
NCT06972992		A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide	P1	completed	28	Ascletis Pharma (China) Co., Limited	Apr 2025
NCT06390501		The Effect of Weekly Semaglutide Treatment on Energy Expenditure	N/A	completed	60	Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences	Apr 2024
NCT06771115		Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity	P2	completed	176	Zomagen Biosciences Ltd.	Jan 2025
NCT05891496		A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease	P3	completed	23	Novo Nordisk A/S	Jun 2023
NCT06541509	SEMAHEART	Mechanisms of Semaglutide Therapy in Heart Failure Patients	P1/P2	recruiting	10	University Medical Centre Ljubljana	Jul 2024
NCT04854083	MitoSema	Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes	P4	unknown	50	Kirsi Pietiläinen	Feb 2022
NCT05444153	PIONEER START	Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity	P3	withdrawn	0	Novo Nordisk A/S	Oct 2022
NCT06282458	QUALITY	Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	P2	completed	168	Veru Inc.	Apr 2024
NCT06045221	ACHIEVE-3	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	P3	completed	1,698	Eli Lilly and Company	Sep 2023
NCT05670379	LIBERATE-1	Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant	P1	completed	24	Vivani Medical, Inc	Dec 2024
NCT06642584		A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV	P1	completed	90	Novo Nordisk A/S	Oct 2024
NCT06648031	DehydraTECH	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants	P1	completed	148	Lexaria Bioscience Corp.	Dec 2024
NCT05895643	SEMALCO	Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?	P2	completed	108	Psychiatric Centre Rigshospitalet	Jun 2023
NCT07096063	TIRZSEMA-CVOT	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	—	completed	887,132	Brigham and Women's Hospital	Oct 2024
NCT06005012	SAMARA	Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM	P2	unknown	120	University of California, San Diego	Jul 2023
NCT05702905		Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome	P4	unknown	75	Peking University First Hospital	May 2023
NCT07056803		Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus	—	completed	212	University of Palermo	Jan 2024
NCT05035082	REALYSE	A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)	P4	completed	1,020	Novo Nordisk A/S	Sep 2021
NCT05616013		Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese	P2	completed	507	Eli Lilly and Company	Nov 2022
NCT06914141	DUP-TIRZSEMA	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	—	completed	28,118	Brigham and Women's Hospital	Jan 2025
NCT06914102	DUP-STEP-HFpEF	Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data	—	completed	58,387	Brigham and Women's Hospital	Jan 2025
NCT06716307		A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity	P1	completed	18	Novo Nordisk A/S	Dec 2024
NCT05813912		A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes	P3	completed	148	Novo Nordisk A/S	Sep 2023
NCT06161844	HD1916	Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus	P3	completed	506	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Feb 2024
NCT04126603		Impact of Semaglutide on CD34+ EPC and Fat Derived MSC	P4	completed	10	Sabyasachi Sen	Aug 2019
NCT05548647	STABLE Wt Loss	Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects	P4	completed	120	University of Pennsylvania	Jul 2022
NCT04469855		Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®	—	completed	3,217	Novo Nordisk A/S	Jul 2020
NCT06041217	STEP12	A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range	P3	completed	242	Novo Nordisk A/S	Sep 2023
NCT07043361	Semaglutide	Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels	—	completed	5,300	Hillel Yaffe Medical Center	Dec 2023
NCT06478550		A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment	—	completed	304	Novo Nordisk A/S	Jun 2024
NCT05303857	SEMA	Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes	P4	completed	107	University of Erlangen-Nürnberg Medical School	Mar 2022
NCT05514535	SUSTAIN OPTIMIZE	A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)	P3	completed	573	Novo Nordisk A/S	Aug 2022
NCT06619015	TOTT	Tailoring Obesity Treatment Trial	P2/P3	withdrawn	0	Esbjerg Hospital - University Hospital of Southern Denmark	Apr 2025
NCT06555146	Sema-RMA	Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy	N/A	not yet recruiting	15	Bispebjerg Hospital	Aug 2024
NCT06468748		The Effects of Semaglutide on Body Composition and Performance in Military Personnel	P4	withdrawn	0	United States Army Research Institute of Environmental Medicine	Aug 2024
NCT05016882	NASH	Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)	P2	completed	698	Novo Nordisk A/S	Aug 2021
NCT05813925		A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight	P3	completed	331	Novo Nordisk A/S	Apr 2023
NCT06863363		PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults	P4	not yet recruiting	212	Shanghai Zhongshan Hospital	—
NCT06659679		Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims	—	completed	26,126	Brigham and Women's Hospital	Oct 2024
NCT06659744		Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims	—	completed	158,310	Brigham and Women's Hospital	Oct 2024
NCT05779644		Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	N/A	unknown	300	RenJi Hospital	Feb 2023
NCT05996848	REDEFINE 6	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight	P3	completed	300	Novo Nordisk A/S	Aug 2023
NCT06659718		Emulation of the SOUL Diabetes Trial in Healthcare Claims	—	completed	43,650	Brigham and Women's Hospital	Oct 2024
NCT05394519	REDEFINE 2	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight	P3	completed	1,200	Novo Nordisk A/S	Feb 2023
NCT05078255		The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes	N/A	completed	61	Asger Lund, MD	Jan 2022
NCT05950516		Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes	P3	unknown	478	Qilu Pharmaceutical Co., Ltd.	Jul 2023
NCT05890976	OASIS 3	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	P3	completed	200	Novo Nordisk A/S	May 2023
NCT06361823		Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment	P3	unknown	74	Capital Medical University	May 2024
NCT06149260		Subcutaneous Semaglutide in Systemic Scleroderma	P1	unknown	10	Second Xiangya Hospital of Central South University	Feb 2024
NCT06243536		The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients	P4	unknown	60	University Hospital Sestre Milosrdnice	Feb 2024
NCT06057077		Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus	P1/P2	unknown	120	Ministry of Health, Saudi Arabia	Jan 2024
NCT05788965		Semaglutide in CFRD	P2/P3	completed	8	University of Minnesota	Oct 2023
NCT05870462	SEMA-VR	Semaglutide and Vascular Regeneration	P4	unknown	100	Canadian Medical and Surgical Knowledge Translation Research Group	Apr 2023
NCT03659682	GIPD	GLP1R in Parkinson's Disease	P2	unknown	120	Oslo University Hospital	Jan 2019
NCT04466345		Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder	P2	completed	72	University Health Network, Toronto	Oct 2021
NCT06507475	REALISED	Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes	—	completed	209	Novo Nordisk A/S	Sep 2024
NCT05649137		A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight	P3	completed	512	Novo Nordisk A/S	Jan 2023
NCT06363487	OxSENSE	Semaglutide and Cognition in Healthy Volunteers	N/A	completed	70	University of Oxford	Jun 2024
NCT04971785	WAYFIND	Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	P2	completed	457	Gilead Sciences	Aug 2021
NCT06422624		A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects	P1	unknown	14	Bostal Drug Delivery Co., Ltd	Aug 2024
NCT04885634	SOCRATES-AF	Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients	P3	withdrawn	0	Axel Brandes	Oct 2022
NCT05579249		A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America	P4	completed	500	Novo Nordisk A/S	Jan 2023
NCT05646706	STEP UP	A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)	P3	completed	1,407	Novo Nordisk A/S	Jan 2023
NCT06207877		A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight	P1	completed	62	Novo Nordisk A/S	Feb 2024
NCT04865770	REMODEL	A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)	P3	completed	106	Novo Nordisk A/S	Apr 2021
NCT04779697		GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight	P1	completed	96	Yale University	Feb 2021
NCT05443568	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice	—	completed	155	Novo Nordisk A/S	Mar 2023
NCT06289504		A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight	P1	completed	34	Novo Nordisk A/S	Feb 2024
NCT05822830	SURMOUNT-5	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	P3	completed	751	Eli Lilly and Company	Apr 2023
NCT05302596		Semaglutide Use in Elderly Obese Patients	P2	completed	16	State University of New York at Buffalo	Sep 2022
NCT05920889	GALLOP	Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies	P2	completed	140	Chinese University of Hong Kong	Aug 2023
NCT05755360	DOORS	DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy	—	completed	291	Novo Nordisk A/S	Feb 2023
NCT04979130	SIB	Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)	P4	completed	69	University of Colorado, Denver	Jan 2022
NCT05897372	WP3	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study	P2	terminated	1	Iain Bressendorff	Aug 2023
NCT06500429	GLP-1	A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist	P2	completed	120	Neurogastrx, Inc.	Jun 2024
NCT03914326	SOUL	A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes	P3	completed	9,651	Novo Nordisk A/S	Jun 2019
NCT06974825		A Study of BGM0504 in Chinese Patients With Type 2 Diabetes	P2	completed	67	BrightGene Bio-Medical Technology Co., Ltd.	Aug 2023
NCT05537233	ADJUST-T1D	ADJUnct Semaglutide Treatment in Type 1 Diabetes	P2	completed	115	Viral N. Shah	Apr 2023
NCT05751226		A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906	P1	completed	88	Boehringer Ingelheim	Apr 2023
NCT06256549		A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus	P2	unknown	272	Gan and Lee Pharmaceuticals, USA	Aug 2023
NCT04560998	STRIDE	A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes	P3	completed	792	Novo Nordisk A/S	Oct 2020
NCT05443334	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	—	completed	465	Novo Nordisk A/S	Jul 2022
NCT06475586		Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus	P4	completed	30	University of Banja Luka	May 2023
NCT05502562	PIONEER REAL	A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India	—	completed	388	Novo Nordisk A/S	Feb 2023
NCT05087342	LSS	Latino Semaglutide Study	P3	completed	119	Loma Linda University	Dec 2022
NCT04889183	SMART	SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes	P3	completed	125	University Medical Center Groningen	Mar 2022
NCT06699329	MK-0616	A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)	P1	completed	38	Merck Sharp & Dohme LLC	Jan 2024
NCT05786521		Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults	P4	completed	20	The University of Texas Health Science Center at San Antonio	Apr 2023
NCT05473286	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice	—	withdrawn	0	Novo Nordisk A/S	Sep 2022
NCT05530577		Effects of Semaglutide on Nicotine Intake	P2	completed	24	University of North Carolina, Chapel Hill	Oct 2022
NCT05564117	OASIS 4	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range	P3	completed	307	Novo Nordisk A/S	Oct 2022
NCT06301191		The Effect of Semaglutide on Cardiovascular Markers and Liver Function	—	unknown	50	Attikon Hospital	Mar 2022
NCT05193578	HISTORI	Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes	P2	completed	154	Jan Frystyk	Jan 2022
NCT05597202	DOTAFLAME	Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes	P4	unknown	22	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Jan 2023
NCT05520775		Semaglutide for Alcohol Use Disorder	P2	completed	48	University of North Carolina, Chapel Hill	Sep 2022
NCT05996874		A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants	P1	completed	121	Novo Nordisk A/S	Aug 2023
NCT05316662		A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice	—	completed	187	Novo Nordisk A/S	Apr 2022
NCT06629688		Semaglutide and Intestinal Iron Absorption	N/A	completed	51	University Hospital Dubrava	Nov 2023
NCT06351748	SCHOLAR	Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)	—	completed	34,238	Novo Nordisk A/S	Jan 2024
NCT05784402		A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants	P1	completed	264	Novo Nordisk A/S	Mar 2023
NCT06097390		A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III	P1	completed	121	Novo Nordisk A/S	Sep 2023
NCT05766709		A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations	P1	completed	53	Novo Nordisk A/S	Mar 2023
NCT05533632		Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes	P4	completed	104	Novo Nordisk A/S	Apr 2022
NCT05259033	COMBINE 2	A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)	P3	completed	683	Novo Nordisk A/S	Apr 2022
NCT03819153	FLOW	A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease	P3	completed	3,533	Novo Nordisk A/S	Jun 2019
NCT05990374		Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years	N/A	unknown	100	Nanjing First Hospital, Nanjing Medical University	Aug 2023
NCT05390307	OTID	Obesity Treatment to Improve Diabetes	N/A	completed	60	Dasman Diabetes Institute	Apr 2023
NCT05768945	DREAM	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors	—	completed	742,670	Brigham and Women's Hospital	Nov 2022
NCT05486065		A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight	P2	completed	245	Novo Nordisk A/S	Aug 2022
NCT05616052		Comparison of Body Weight Change Through Different Smeglutide Administration Methods	P4	unknown	80	Huashan Hospital	Dec 2022
NCT05147896	SAMAS	Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients	N/A	unknown	100	University Medical Centre Ljubljana	May 2022
NCT04998136		Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity	P3	completed	150	Novo Nordisk A/S	Aug 2022
NCT05671653		A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range	P1	terminated	32	Pfizer	Jan 2023
NCT04538352	TRANSITION-T2D	Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D	P4	completed	60	The Cleveland Clinic	Jan 2021
NCT05816057		A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus	P3	completed	476	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,	Jul 2022
NCT05230615	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	—	completed	458	Novo Nordisk A/S	Apr 2022
NCT04916470	STEP HFpEF DM	Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes	P3	completed	617	Novo Nordisk A/S	Jun 2021
NCT03919929	TEAL	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	P2/P3	completed	60	University of Colorado, Denver	May 2019
NCT05478252		A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes	P3	completed	388	Novo Nordisk A/S	Aug 2022
NCT04216589	NAFLD	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	P2	completed	51	National Institute of Allergy and Infectious Diseases (NIAID)	Feb 2021
NCT05064735		Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis	P3	completed	407	Novo Nordisk A/S	Oct 2021
NCT05132088	OASIS 2	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity	P3	completed	201	Novo Nordisk A/S	Nov 2021
NCT04862923	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice	—	completed	336	Novo Nordisk A/S	May 2021
NCT06154486		Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study	—	completed	30	Hospital Israelita Albert Einstein	Jun 2023
NCT05227196		A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People	P1	completed	546	Novo Nordisk A/S	Feb 2022
NCT05606471	SemVLCD	Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets	P4	unknown	45	University of Nottingham	Sep 2021
NCT05040971	STEP 10	Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes	P3	completed	207	Novo Nordisk A/S	Sep 2021
NCT05716724	O-SEMA-Fast	O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait	—	completed	288	Novo Nordisk A/S	Jan 2023
NCT04817644		A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets	P1	completed	14	Novo Nordisk A/S	Sep 2021
NCT06354101		The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	—	withdrawn	0	CorEvitas	Jul 2023
NCT05442450	OSO	Efficacy of Oral Semaglutide in Overweight or Obesity	P4	unknown	116	Asian Institute of Gastroenterology, India	Jul 2022
NCT06489457	SEMAT	The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity	P3	completed	25	University Medical Centre Ljubljana	Sep 2020
NCT03574597	SELECT	Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity	P3	completed	17,604	Novo Nordisk A/S	Oct 2018
NCT03596450		Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial	P4	completed	1,278	Novo Nordisk A/S	Jul 2018
NCT04032197		A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes	P1	completed	101	Novo Nordisk A/S	Aug 2019
NCT04537624	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice	—	completed	194	Novo Nordisk A/S	Aug 2020
NCT05689099		A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose	P1	completed	20	Novo Nordisk A/S	Jan 2023
NCT05035095	OASIS 1	Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)	P3	completed	667	Novo Nordisk A/S	Sep 2021
NCT04537637	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice	—	completed	99	Novo Nordisk A/S	Aug 2020
NCT05129891		A Research Study Looking at New Protein-based Tablets in Healthy Male Participants	P1	completed	384	Novo Nordisk A/S	Nov 2021
NCT05443191	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice	—	completed	50	Novo Nordisk A/S	Oct 2022
NCT05435677		A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together	P1	completed	20	Novo Nordisk A/S	Jun 2022
NCT05857085	ENDIS	Novel Therapeutics and Endothelial Dysfunction in T1DM Patients	P4	completed	90	General and Teaching Hospital Celje	Dec 2021
NCT04788511	STEP-HFpEF	Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity	P3	completed	529	Novo Nordisk A/S	Mar 2021
NCT05429593		A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet	P1	completed	152	Novo Nordisk A/S	Jun 2022
NCT05144984		A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes	P2	completed	500	Novo Nordisk A/S	Nov 2021
NCT05230589	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice	—	completed	194	Novo Nordisk A/S	Apr 2022
NCT04707469	PIONEER PLUS	Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes	P3	completed	1,606	Novo Nordisk A/S	Jan 2021
NCT06118203		Semaglutide Use in Acute Pulmonary Embolism	—	completed	18	Imperial College London	Jan 2022
NCT04601753	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice	—	completed	194	Novo Nordisk A/S	Nov 2020
NCT03292315		Once Weekly GLP-1 in Persons With Spinal Cord Injury	P4	completed	5	James J. Peters Veterans Affairs Medical Center	Oct 2018
NCT04938388		Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care	P4	terminated	12	Sansum Diabetes Research Institute	Jan 2022
NCT04878393	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice	—	completed	650	Novo Nordisk A/S	Apr 2021
NCT04741074	RAISE-KT	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	P3	terminated	15	Geisinger Clinic	Jul 2021
NCT04969939		A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity	P2	completed	120	Novo Nordisk A/S	Jul 2021
NCT05249881		"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."	Early P1	unknown	300	Aga Khan University	Mar 2022
NCT03985384	STOP	Semaglutide Treatment On Coronary Progression	P4	completed	140	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Apr 2019
NCT04601740	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice	—	completed	145	Novo Nordisk A/S	Nov 2020
NCT05236517		A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity	P1	completed	60	Novo Nordisk A/S	Feb 2022
NCT05577728		Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data	—	completed	2,316	Brigham and Women's Hospital	Jul 2021
NCT04944992	MK-6024	A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)	P2	completed	145	Merck Sharp & Dohme LLC	Aug 2021
NCT05498610		A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men	P1	completed	24	Novo Nordisk A/S	Aug 2022
NCT04559815	PIONEER REAL	A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice	—	completed	194	Novo Nordisk A/S	Oct 2020
NCT04447859		16-week Flexible vs. 8-week Semaglutide Titration	P3	unknown	100	Tel-Aviv Sourasky Medical Center	Feb 2020
NCT05153564		A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause	P1	completed	27	Novo Nordisk A/S	Dec 2021
NCT04383197	EXISECRET	Exercise and GLP-1 RA on Insulin Secretion	N/A	unknown	30	University of Copenhagen	Dec 2019
NCT05232708		A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide	P1	completed	18	Novo Nordisk A/S	Jan 2022
NCT04251156	STEP7	Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.	P3	completed	375	Novo Nordisk A/S	Dec 2020
NCT04624672	NOVO-GLP1	Treatment of GLP-1 for Diabetic Bariatric Patients	P4	terminated	3	Geisinger Clinic	Aug 2021
NCT05468632	MIRAGE	A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)	—	completed	314	Novo Nordisk A/S	Jul 2022
NCT04982575		Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes	P2	completed	92	Novo Nordisk A/S	Aug 2021
NCT04615871	SEMPATICO	Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19	P2	unknown	400	Vladimír Džavík	Sep 2021
NCT04102189		A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity	P3	completed	201	Novo Nordisk A/S	Oct 2019
NCT04259801		First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes	P1	completed	152	Novo Nordisk A/S	Feb 2020
NCT04515849		A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus	P2	completed	248	AstraZeneca	Aug 2020
NCT04524832		Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People	P1	completed	290	Novo Nordisk A/S	Sep 2020
NCT04940078		A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity	P1	completed	40	Novo Nordisk A/S	Jul 2021
NCT05046873		A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People	P1	completed	16	Novo Nordisk A/S	Sep 2021
NCT04153929		A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.	P2	completed	413	Boehringer Ingelheim	Apr 2020
NCT04263415		The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity	P4	completed	30	University Medical Centre Ljubljana	Nov 2019
NCT04109547	PIONEER 11	A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes	P3	completed	521	Novo Nordisk A/S	Oct 2019
NCT04017832	PIONEER 12	A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes	P3	completed	1,441	Novo Nordisk A/S	Jul 2019
NCT04865744		The Effect of Semaglutide on Pituitary Function	P4	completed	10	University of Tartu	May 2021
NCT04083820	SURE FRANCE	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)	—	completed	521	Novo Nordisk A/S	Sep 2019
NCT04061200	EmpaSema	Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria	P4	unknown	80	Steno Diabetes Center Copenhagen	Nov 2019
NCT04094415	SURE ITALY	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	—	completed	581	Novo Nordisk A/S	Oct 2019
NCT04878406		A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men	P1	completed	24	Novo Nordisk A/S	May 2021
NCT04067999	SURE SPAIN	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	—	completed	230	Novo Nordisk A/S	Aug 2019
NCT03987451		A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage	P2	completed	71	Novo Nordisk A/S	Jun 2019
NCT04513704		A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times	P1	completed	156	Novo Nordisk A/S	Aug 2020
NCT04261933	SURE GERMANY	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)	—	completed	789	Novo Nordisk A/S	Feb 2020
NCT04074161	STEP 8	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity	P3	completed	338	Novo Nordisk A/S	Sep 2019
NCT03951753	T2DM	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	P1	completed	117	Eli Lilly and Company	Jun 2019
NCT03693430	STEP 5	Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	P3	completed	304	Novo Nordisk A/S	Oct 2018
NCT03548935	STEP 1	STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	P3	completed	1,961	Novo Nordisk A/S	Jun 2018
NCT04016974		A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese	P1	completed	32	Novo Nordisk A/S	Oct 2019
NCT03689374	SUSTAIN 11	A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes	P3	completed	2,274	Novo Nordisk A/S	Oct 2018
NCT03987919	SURPASS-2	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	P3	completed	1,879	Eli Lilly and Company	Jul 2019
NCT04109508	C	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets	P1	completed	278	Novo Nordisk A/S	Oct 2019
NCT04287179	SUSTAIN SWITCH	SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	P3	withdrawn	0	Novo Nordisk A/S	Mar 2020
NCT04097600	D	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets	P1	completed	274	Novo Nordisk A/S	Sep 2019
NCT03929679	SURE NL	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)	—	completed	218	Novo Nordisk A/S	May 2019
NCT03811574	STEP 6	STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity	P3	completed	401	Novo Nordisk A/S	Jan 2019
NCT03989232	SUSTAIN FORTE	A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	P3	completed	961	Novo Nordisk A/S	Jun 2019
NCT04238962		A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens	P1	completed	111	Novo Nordisk A/S	Feb 2020
NCT04187300		A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	P1	completed	68	Novo Nordisk A/S	Dec 2019
NCT03876015	SURE UK	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)	—	completed	215	Novo Nordisk A/S	May 2019
NCT03987074	NASH	Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)	P2	completed	109	Gilead Sciences	Jul 2019
NCT03600480		A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese	P1	completed	96	Novo Nordisk A/S	Jul 2018
NCT04228354		A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide	P1	completed	28	Novo Nordisk A/S	Jan 2020
NCT04152915		A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens	P1	completed	68	Novo Nordisk A/S	Nov 2019
NCT03552757	STEP 2	Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity	P3	completed	1,210	Novo Nordisk A/S	Jun 2018
NCT03611582	STEP 3	Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program	P3	completed	611	Novo Nordisk A/S	Aug 2018
NCT03548987	STEP 4	Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity	P3	completed	902	Novo Nordisk A/S	Jun 2018
NCT03357380		A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver	P1	completed	67	Novo Nordisk A/S	Nov 2017
NCT02970942		Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	P2	completed	320	Novo Nordisk A/S	Nov 2016
NCT04189848		Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc	P4	completed	104	Novo Nordisk A/S	Dec 2019
NCT04175665		Real-world Health Outcomes in Canadian Patients Using Semaglutide	—	completed	1,133	LMC Diabetes & Endocrinology Ltd.	Jan 2020
NCT03648281		A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)	—	completed	333	Novo Nordisk A/S	Aug 2018
NCT04143945		A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	P2	completed	104	Novo Nordisk A/S	Oct 2019
NCT03457012	SURE CANADA	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice	—	completed	462	Novo Nordisk A/S	Mar 2018
NCT03631186	SURE SWITZERLAND	A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)	—	completed	215	Novo Nordisk A/S	Sep 2018
NCT03842202		A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity	P1	completed	72	Novo Nordisk A/S	Feb 2019
NCT04012255		A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity	P1	terminated	29	Novo Nordisk A/S	Jul 2019
NCT03789578		A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together	P1	completed	30	Novo Nordisk A/S	Jan 2019
NCT04007107		A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity	P2	completed	103	Novo Nordisk A/S	Jun 2019
NCT03707990		A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese	P1	completed	88	Novo Nordisk A/S	Oct 2018
NCT03574584		A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese	P1	completed	37	Novo Nordisk A/S	Jun 2018
NCT03061214	SUSTAIN	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)	P3	completed	868	Novo Nordisk A/S	Aug 2017
NCT03724981		A Study Comparing the Dulaglutide Pen and the Semaglutide Pen	P4	completed	312	Eli Lilly and Company	Oct 2018
NCT02849080	PIONEER 7	Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.	P3	completed	504	Novo Nordisk A/S	Sep 2016
NCT03598621		A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools	P1	completed	68	Novo Nordisk A/S	Jul 2018
NCT03611322		A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)	P1	completed	54	Novo Nordisk A/S	Aug 2018
NCT03638778		Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men	P1	completed	105	Novo Nordisk A/S	Aug 2018
NCT03136484	SUSTAIN 8	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes	P3	completed	788	Novo Nordisk A/S	Mar 2017
NCT02773381		A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes	P1	completed	15	Novo Nordisk A/S	Jun 2016
NCT02692716	PIONEER 6	A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes	P3	completed	3,183	Novo Nordisk A/S	Jan 2017
NCT03021187	PIONEER 8	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin	P3	completed	731	Novo Nordisk A/S	Feb 2017
NCT03018028	PIONEER 9	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes	P3	completed	243	Novo Nordisk A/S	Jan 2017
NCT03191396	SUSTAIN 10	Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes	P3	completed	577	Novo Nordisk A/S	Jun 2017
NCT03288740		A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects	P1	completed	36	Novo Nordisk A/S	Sep 2017
NCT03086330	SUSTAIN 9	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus	P3	completed	302	Novo Nordisk A/S	Mar 2017
NCT03015220	PIONEER 10	Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes	P3	completed	458	Novo Nordisk A/S	Jan 2017
NCT03466567		A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects	P1	completed	21	Novo Nordisk A/S	Mar 2018
NCT02827708	PIONEER 5	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment	P3	completed	324	Novo Nordisk A/S	Sep 2016
NCT02863419	PIONEER 4	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus	P3	completed	711	Novo Nordisk A/S	Aug 2016
NCT02607865	PIONEER 3	Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	P3	completed	1,864	Novo Nordisk A/S	Feb 2016
NCT02863328	PIONEER 2	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus	P3	completed	822	Novo Nordisk A/S	Aug 2016
NCT02906930	PIONEER 1	Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only	P3	completed	703	Novo Nordisk A/S	Sep 2016
NCT02877355		Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.	P1	completed	55	Novo Nordisk A/S	Aug 2016
NCT03010475		A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects	P1	completed	41	Novo Nordisk A/S	Jan 2017
NCT02920385		A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.	P1	completed	45	Novo Nordisk A/S	Oct 2016
NCT02648204	SUSTAIN 7	Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.	P3	completed	1,201	Novo Nordisk A/S	Jan 2016
NCT02453711		Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus	P2	completed	957	Novo Nordisk A/S	Oct 2015
NCT02845219		A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females	P1	completed	25	Novo Nordisk A/S	Jul 2016
NCT02461589		Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes	P2	completed	706	Novo Nordisk A/S	Sep 2015
NCT02557620		Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly	P1	completed	113	Novo Nordisk A/S	Sep 2015
NCT01720446	SUSTAIN™ 6	Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes	P3	completed	3,297	Novo Nordisk A/S	Feb 2013
NCT02207374	SUSTAIN™	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes	P3	completed	601	Novo Nordisk A/S	Aug 2014
NCT02305381	SUSTAIN™ 5	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes	P3	completed	397	Novo Nordisk A/S	Dec 2014
NCT02254291	SUSTAIN™	A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes	P3	completed	308	Novo Nordisk A/S	Oct 2014
NCT01930188	SUSTAIN™ 2	Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes	P3	completed	1,231	Novo Nordisk A/S	Dec 2013
NCT02128932	SUSTAIN™ 4	Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes	P3	completed	1,089	Novo Nordisk A/S	Aug 2014
NCT01885208	SUSTAIN™ 3	Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes	P3	completed	813	Novo Nordisk A/S	Dec 2013
NCT02210871		Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function	P1	completed	44	Novo Nordisk A/S	Aug 2014
NCT02147431		A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	P1	completed	38	Novo Nordisk A/S	May 2014
NCT02212067		A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes	P1	completed	87	Novo Nordisk A/S	Aug 2014
NCT02054897	SUSTAIN™1	Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes	P3	completed	388	Novo Nordisk A/S	Feb 2014
NCT02064348		A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects	P1	completed	168	Novo Nordisk A/S	Feb 2014
NCT02243098		Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects	P1	completed	31	Novo Nordisk A/S	Sep 2014
NCT02249871		Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	P1	completed	54	Novo Nordisk A/S	Sep 2014
NCT02249910		Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects	P1	completed	32	Novo Nordisk A/S	Sep 2014
NCT02231684		Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide	P1	completed	42	Novo Nordisk A/S	Sep 2014
NCT02016911		Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment	P1	completed	56	Novo Nordisk A/S	Dec 2013
NCT02079870		Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo	P1	completed	30	Novo Nordisk A/S	Mar 2014
NCT01923181		Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes	P2	completed	632	Novo Nordisk A/S	Dec 2013
NCT02161588		A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects	P1	completed	48	Novo Nordisk A/S	Jun 2014
NCT02172313		Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects	P1	completed	78	Novo Nordisk A/S	Jun 2014
NCT02014259		Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function	P1	completed	71	Novo Nordisk A/S	Dec 2013
NCT02146079		A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects	P1	completed	44	Novo Nordisk A/S	May 2014
NCT02022254		Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects	P1	completed	24	Novo Nordisk A/S	Dec 2013
NCT02070510		A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects	P1	completed	52	Novo Nordisk A/S	Feb 2014
NCT01866748		Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects	P1	completed	170	Novo Nordisk A/S	May 2013
NCT02060266		Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects	P1	completed	7	Novo Nordisk A/S	Feb 2014
NCT01766245		A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes	P1	completed	28	Novo Nordisk A/S	Dec 2012
NCT01686945		Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes	P1	completed	107	Novo Nordisk A/S	Sep 2012
NCT01572753		Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects	P1	completed	161	Novo Nordisk A/S	Apr 2012
NCT01619345		Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects	P1	completed	27	Novo Nordisk A/S	Jun 2012
NCT01324505		Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes	P1	completed	43	Novo Nordisk A/S	Mar 2011
NCT01272973		Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects	P1	completed	96	Novo Nordisk A/S	Jan 2011
NCT00833716		Effect of Renal Impairment on the Pharmacokinetics of NN9535	P1	completed	62	Novo Nordisk A/S	Feb 2009
NCT00851773		Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects	P1	completed	84	Novo Nordisk A/S	Feb 2009
NCT00813020		A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects	P1	completed	44	Novo Nordisk A/S	Jan 2009
NCT00696657		A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	P2	completed	415	Novo Nordisk A/S	Jun 2008
NCT03144271		Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects	P1	completed	58	Novo Nordisk A/S	Jun 2007

Semaglutide clinical trials: frequently asked questions

How many Semaglutide clinical trials are there?: 537 Semaglutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 114 are actively recruiting participants. 279 are marked completed.
Are Semaglutide clinical trials recruiting in 2026?: Yes — 114 Semaglutide trials are actively recruiting in 2026, with 195 U.S. sites across 37 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Semaglutide being studied for?: Semaglutide is being studied for Diabetes Mellitus, Type 2, Obesity, Diabetes, Type 2 Diabetes, Overweight and 329 more. The trials are grouped by indication on this page.
What phase is Semaglutide in?: Semaglutide clinical trials span 85 Phase 4, 138 Phase 3, 95 Phase 2, 104 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Semaglutide clinical trials?: The lead sponsor across the most Semaglutide trials is Novo Nordisk A/S, with 213 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Semaglutideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Semaglutide overview Semaglutide evidence & publications